Phage genome editing by a combination of crispr / cas and a TET-like protein

By using a Tet-like protein to reduce hypermodifications in phage DNA, the efficiency of CRISPR-Cas genome editing in phages is enhanced, overcoming the limitations of existing methods and enabling precise manipulation of phage genes with minimal impact on phage fitness.

WO2024240867A1PCT designated stage expired Publication Date: 2024-11-28MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/064199
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods for site-specific phage mutagenesis, particularly using CRISPR-Cas technology, face inefficiencies due to hypermodifications in phage DNA, such as 5-hydroxymethyl-2'-deoxycytosine, which protect viral genetic material from degradation by host restriction enzymes, limiting the precision and effectiveness of genome editing in phages like T4.

Method used

Incorporating a Tet-like protein, which reduces the abundance of sterically demanding cytosine modifications by converting 5-hydroxymethyl-2'-deoxycytosine into 5-formyl-2'-deoxycytosine and 5-carboxy-2'-deoxycytosine, thereby enhancing the accessibility and efficiency of CRISPR-Cas nucleases to introduce targeted DNA breaks in the phage genome.

Benefits of technology

This approach significantly improves the efficiency of CRISPR-Cas-mediated genome editing in phages by increasing the accessibility of target sites to Cas nucleases, leading to a substantial increase in mutagenesis rates and allowing for more precise manipulation of phage genes, while the reversibility of cytosine hypermodifications ensures minimal impact on phage fitness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000021_0001
    Figure IMGF000021_0001
  • Figure IMGF000027_0001
    Figure IMGF000027_0001
  • Figure IMGF000028_0001
    Figure IMGF000028_0001
Patent Text Reader

Abstract

The present invention relates to a method for genetically engineering the genome of phages at a target locus by CRISPR-Cas, where the phases the genome of which is to be genetically engineered are comprises in a bacterial cell, a L-form bacterium, a cell-free transcription-translation system (TXTL) system or a bacterial cell lysate expressing a Tet-like protein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Phage genome editing by a combination of CRISPR / Cas and a Tet-like protein

[0002] The present invention relates to a method for genetically engineering the genome of phages at a target locus by CRISPR-Cas comprising (a) introducing into a bacterial cell, a L-form bacteria, a cell-free transcription-translation system (TXTL) system or a bacterial cell lysate expressing or comprising a Tet- like protein and comprising the phages the genome of which is to be genetically engineered (I) one or more nucleic acid molecules, said one or more nucleic acid molecules encoding in expressible form (i) a CRISPR-Cas nuclease, and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; (II) (i) a CRISPR-Cas nuclease, (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus, (III) (i) a CRISPR-Cas nuclease, and (ii) a nucleic acid molecule encoding in expressible form a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; (IV) (i) a nucleic acid molecule encoding in expressible form a CRISPR-Cas nuclease, and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; or (V) (i) a ribonucleoprotein complex (RNP) comprising or consisting of a CRISPR-Cas nuclease in complex with a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease, and (ii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; and (b) maintaining the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate under conditions wherein the genome of the phages becomes genetically engineered by the CRISPR-Cas nuclease, optionally by homology directed repair (HDR) in the case the donor template is present.

[0003] In this specification, a number of documents including patent applications and manufacturer’s manuals are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference. Phages are viruses that specifically infect prokaryotic hosts. The high potential of phage utilization in both medical and industrial settings boosted phage research in recent years. However, despite the potential applications (Endersen, O'Mahony et al. 2014, Gordillo Altamirano and Barr 2019, Mahony, Casey et al. 2020), the phage biology and mechanisms of phage-host interactions remain poorly understood. This is also the case even for well-studied phages such as Escherichia coli bacteriophage T4. Although T4 is one of the first and most extensively studied phages, its control take-over mechanisms over the host E. coli are not yet fully resolved. Only about half of 273 proteins encoded by T4 phage are linked to a specific biological function, while the role of the others remains unknown (Wolfram-Schauerte, Pozhydaieva et al. 2022).

[0004] In the past, UV-mediated gene deletion was a standard approach to determine the biological function of phage genes and proteins. UV-based mutagenesis of T4 phage provided initial insights into the relevance of specific T4 phage genes for infection and their classification into essential, auxiliary, and non-essential genes (Drake 1966, Miller, Kutter et al. 2003). However, UV-meditated phage mutagenesis cannot be applied to introduce the mutations in a site-specific manner, which significantly limits its applicability. Due to the complexity of T4 phage genetics, which includes overlapping and spliced genes (Miller, Kutter et al. 2003), site-specific mutagenesis combined with rational mutagenesis design is beneficial to delete target genes or even better - to disrupt their expression or abolish the catalytic activity of their protein products. In such a way, the unambiguous study of a particular gene's role in the infection cycle is possible.

[0005] Several site-specific phage mutagenesis approaches have been reported, including CRISPR-Cas- based mutagenesis (Pires, Cleto et al. 2016, Hatoum-Aslan 2018, Chen, Batra et al. 2019, Mahler, Costa et al. 2022). Here, genome editing occurs in vivo. Upon a phage infection, a Cas nuclease induces a DNA double-strand break at a specific position in viral DNA that can be repaired through homologous recombination with a donor DNA present in situ in form of a plasmid. Different CRISPR-Cas systems were already applied for targeted gene deletion or gene insertion in phage DNA, among them T4 phage (Kiro, Shitrit et al. 2014, Martel and Moineau 2014, Box, McGuffie et al. 2016, Lemay, Tremblay et al. 2017, Tao, Wu et al. 2017, Duong, Carmody et al. 2020, Dong, Chen et al. 2021). However, for the T4 phage, the efficiency of the DNA cleavage and, consequently of the mutation events was on average low. This can be explained by the hypermodification of T4 DNA. Within T4 DNA, all cytosines (dC) are modified to 5-hydroxymethyl-2'-deoxycytosine (5hmdC) and following glycosylated to 5-a- / p-glycosyl hydroxymethyl-2'-deoxycytosine (5ghmdC) by T4 encoded a-or p-glycosyltransferases (a- / p-gt) (Kornberg, Zimmerman et al. 1961 , Flodman, Correa et al. 2020). These hypermodifications protect viral genetic material from degradation by host restriction enzymes, including Cas nucleases. Studies have shown that cleavage of the DNA by Cas nucleases is facilitated in the absence of 5ghmdC, which can be achieved by utilizing a-Zfi-gt T4 mutants (Bryson, Hwang et al. 2015, Vlot, Houkes et al. 2018, Hutinet, Lee et al. 2021). However, the deletion of auxiliary genes a-Z / S-gt might affect phage fitness and would potentially impede the elucidation of the role of other genes. Also, the T4 host, E. coli, does not possess enzymes to degrade the cytosine modifications on T4 DNA to enhance the cleavage of invader DNA.

[0006] Hence, there is still an unmet need for site-specific phage mutagenesis approaches for the genome of phages and in particular such approaches that are based on the CRISPR-Cas technology. This need is addressed by the present invention.

[0007] Hence, the present invention relates in first aspect to a method for genetically engineering the genome of phages at a target locus by CRISPR-Cas comprising (a) introducing into a bacterial cell, L-form bacteria a cell-free transcription-translation system (TXTL) system or a bacterial cell lysate expressing or comprising a Tet-like protein and comprising the phages the genome of which is to be genetically engineered (I) one or more nucleic acid molecules, said one or more nucleic acid molecules encoding in expressible form (i) a CRISPR-Cas nuclease, and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; (II)

[0008] (i) a CRISPR-Cas nuclease, (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus, (III) (i) a CRISPR-Cas nuclease, and (ii) a nucleic acid molecule encoding in expressible form a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; (IV) (i) a nucleic acid molecule encoding in expressible form a CRISPR-Cas nuclease, and

[0009] (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; or (V) (i) a ribonucleoprotein complex (RNP) comprising or consisting of a CRISPR-Cas nuclease in complex with a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease, and (ii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; and (b) maintaining the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate under conditions wherein the genome of the phages becomes genetically engineered by the CRISPR-Cas nuclease, optionally by homology directed repair (HDR) in the case the donor template is present.

[0010] As used herein genetic engineering (also known as genome editing or genome engineering) is a type of genetic engineering in which a gene of interest is genetically modified by double strand break (DSB) that is introduced specifically at a target site. In the absence of donor template the DSB is repaired by non-homologous end-joining (NHEJ). NHEJ is referred to as "non-homologous" because the break ends are directly ligated without the need for a homologous template, in contrast to homologous recombination, which requires a homologous sequence to guide repair. In presence of the donor template the DSB can also be repaired by homology directed recombination (HDR) pathway and the donor template can, for example, insert, delete, modify or replace a nucleic acid sequence at the target site in the genome of the phage. As compared to non-homologous end-joining (NHEJ) HDR is the more accurate mechanism for DSB repair due to the requirement of higher sequence homology between the damaged and intact donor strands of DNA. The process is error-free if the DNA template used for repair is identical to the original DNA sequence at the DSB, or it can introduce specific mutations into the damaged DNA. On the other hand, NHJE is only generally error-free when the overhangs of the DSB are perfectly compatible. Otherwise NHJE repair leads to loss of nucleotides, in particular if the DSB overhangs are not compatible.

[0011] Genetic engineering may result in a loss-of-function mutation or a gain-of-function mutation in the genome of the cell. A loss-of-function mutation (also called inactivating mutation) results in the gene of interest having less or no function (being partially or wholly inactivated). When the allele has a complete loss of function (wholly inactivated) this is also called herein a (gene) knock-out. Genome editing of the gene of interest is preferably a knock-out. A gene knock-out may be achieved by inserting, deleting, modifying or replacing one or more nucleotides of a gene. A gain-of-function mutation (also called activating mutation) may change the gene of interest such that its effect gets stronger (enhanced activation) or even is superseded by a different (e.g. abnormal) function. A gain-of-function mutation may also introduce a new function or effect into a cell which the cell did not have before. In this context the new gene may be added to the genome of the cell (insertion) or may replace a gene within the genome. A gain-of-function mutation introducing such a new function or effect is also called gene knock- in.

[0012] Genetic engineering in accordance with the first aspect of the invention relies on (i) a nuclease of the clustered regularly interspaced short palindromic repeats (CRISPR-Cas) system which is also designated “CRISPR-Cas nuclease” herein, and (ii) a guide RNA that mediates the interaction between CRISPR-Cas nucleases and the target locus which is also referred to herein as “spacer / protospacer”. In the case of genetic engineering by HDR in addition (iii) a donor template with homology to the target locus is required, which is also referred to herein as “HDR template”.

[0013] CRISPR-Cas nucleases (or CRISPR nucleases or Cas nucleases) are a specific type of programmable nucleases. The CRISPR-Cas system has been harnessed for genome editing in prokaryotes, eukaryotes and phages. A small piece of RNA with a short "guide" sequence that attaches (binds) to a specific target sequence of DNA in a genome is created (the so-called guide RNA (gRNA) or single guide (sgRNA)). The genomic target site of the gRNA can be any ~20 nucleotide DNA sequence, provided it meets two conditions: (i) The sequence is unique compared to the rest of the genome, and (ii) the target is present immediately adjacent to a protospacer adjacent motif (PAM). The PAM sequence is essential fortarget binding, but the exact sequence depends on which CRISPR-Cas nuclease is used. CRISPR-Cas nucleases and their respective PAM sequences are known in the art (see https: / / www.addgene.Org / crispr / guide / #pam-table). Hence, the gRNA also binds to the CRISPR-Cas nuclease. The gRNA is used to recognize the DNA sequence, and the CRISPR-Cas nuclease cuts the DNA at the targeted location. Once the DNA is cut, the cell's DNA repair machinery (NHEJ or HDR) adds or deletes pieces of genetic material, or makes changes to the DNA by replacing an existing segment with a customized DNA sequence. Hence, in the CRISPR-Cas system, the CRISPR-Cas nuclease makes a double-stranded break in DNA at a site determined by the short (~20 nucleotides) gRNA which break is then repaired within the cell by NHEJ or HDR. The CRISPR-Cas system can be multiplexed by adding multiple gRNAs. It was demonstrated that, for example, five different simultaneous mutations can be introduced into mouse embryonic stem cells by using five different gRNA molecules and one CRISPR-Cas nuclease.

[0014] The designs and structures of donor templates being suitable for HDR are known in the art. As mentioned, HDR is error-free if the repair template is identical to the original DNA sequence at the double-strand break (DSB), or it can introduce very specific mutations into DNA. The three central steps of the HDR pathways are: (1) The 5’-ended DNA strand is resected at the break to create a 3’ overhang. This will serve as both a substrate for proteins required for strand invasion and a primer for DNA repair synthesis. (2) The invasive strand can then displace one strand of the homologous DNA duplex and pair with the other. This results in the formation of the hybrid DNA, referred to as the displacement loop (D loop). (3) The recombination intermediates can then be resolved to complete the DNA repair process.

[0015] HDR templates used, for example, to introduce mutations or insert new nucleotides (e.g. single nucleotide polymorphisms) or nucleotide sequences into a gene require a certain amount of homology surrounding the target sequence that will be modified. Homology arms can be used that start at the CRISPR-induced DSB. In general, the insertion sites of the modification should be very close to the DSB, ideally less than 10 bp away, if possible. One important point to note is that the CRISPR enzymes may continue to cleave DNA once a DSB is introduced and repaired. As long as the gRNA target site / PAM site remain intact, the CRISPR-Cas nuclease will keep cutting and repairing the DNA (perfectly or with mismatches). This repeated editing may be problematic if a very specific mutation or sequence is to be introduced into a gene of interest. To get around this, the repair template can be designed in such a way that it will ultimately block further CRISPR-Cas nuclease targeting after the initial DSB is repaired. Two common ways to block further editing are mutating the PAM sequence or the gRNA seed sequence. When designing a repair template, the size of the intended edit is to be taken into consideration. ssDNA templates (also referred to as ssODNs) are commonly used for smaller modifications. Small insertions / edits may require as little as 30-50 bases for each homology arm, and the best exact number may vary based on the gene of interest. 50-80 base homology arms are commonly used. For example, Richardson et al. (Nat Biotechnol. 2016 Mar; 34(3):339-44) found that asymmetric homology arms (36 bases distal to the PAM and 91 bases proximal to the PAM) supported HDR efficiencies up to 60%. Due to difficulties that might be associated with creating ssODNs longer than 200 bases, it is preferred to use dsDNA plasmid repair templates for larger insertions such as fluorescent proteins or selection cassettes into a gene of interest. These templates can have homology arms of at least 800 bp. To increase the frequency of HDR edits based on plasmid repair templates, self-cleaving plasmids can be used that contain gRNA target sites flanking the template. When the CRISPR-Cas nuclease and the appropriate gRNA(s) are present, the template is liberated from the vector. To avoid plasmid cloning, it is possible to use PCR-generated long dsDNA templates. Moreover, Quadros et al. (Genome Biol. 2017 May 17;18(1):92) developed Easi-CRISPR, a technique that allows making large mutations and to take advantage of the benefits of ssODNs. To create ssODNs longer than 200 bases, RNA encoding the repair template are in vitro transcribed and then reverse transcriptase is used to create the complementary ssDNA. Easi-CRISPR works well in mouse knock-in models, increasing editing efficiency from 1-10% with dsDNA to 25-50% with ssODNs. Although HDR efficiency varies across loci and experimental systems, ssODN templates generally provide the highest frequency of HDR edits.

[0016] The target locus (also referred to as “target site” herein) is not particularly limited and refers to a genomic site of interest that is present in the genome of cells to be genome edited. The target site in the genome designates mitochondrial DNA or genomic DNA and preferably genomic DNA. The target site is preferably but not necessarily a gene of interest (or target gene). The target site may also be, for example, a gene regulatory element, such as a promoter region or a cis-regulatory element.

[0017] A phage is a duplodnaviria virus that infects and replicates within bacteria and archaea. Phages are composed of proteins that encapsulate a DNA or RNA genome, and may have structures that are either simple or elaborate. Their genomes may encode as few as four genes (e.g. MS2) and as many as hundreds of genes. Phages replicate within the bacterium or archaea following the injection of their genome into its cytoplasm. Phages can also replicate in a L-form bacterium, a cell-free transcriptiontranslation system (TXTL) system or a bacterial cell lysate.

[0018] The phages can be comprised in a bacterium, a L-form bacterium, a TXTL system or a bacterial cell lysate in the form of a bacteriophage or prophage, preferably bacteriophage. A prophage is a bacteriophage genome that is integrated into the circular bacterial chromosome or exists as an extrachromosomal plasmid within the bacterial cell, L-form bacterium, TXTL system or a bacterial cell lysate. On the other hand, a bacteriophage refers to the “free” form of the phage as comprised in the bacterial cell, L-form bacterium, TXTL system or a bacterial cell lysate. This "free" form is generally phage particles.

[0019] Bacterial cells (or bacteria) are prokaryotes, lacking well-defined nuclei and membrane-bound organelles, and with chromosomes composed of a single closed DNA circle. As discussed herein above, phages are not capable of replicating autonomously but require a host bacterium for their replication (or propagation). For this, the phages need to be comprised in the host bacterium, which usually is the result of the infection of the host bacterium by the phages.

[0020] Instead of propagating phages in a bacterial cell also, a L-form bacterium, a TXTL system or a bacterial cell lysate can be used. L-form bacteria (also known as L-phase bacteria, L-phase variants or cell wall-deficient (CWD) bacteria) are growth forms derived from different bacteria. They lack cell walls. Two types of L-forms are distinguished: unstable L-forms, spheroplasts that are capable of dividing, but can revert to the original morphology, and stable L-forms, L-forms that are unable to revert to the original bacteria.

[0021] Cell-free transcription-translation (TXTL) systems are art-established as suitable platforms to tackle such topics because they recapitulate the process of gene expression. With TXTL systems the in vitro construction of viable, complex, self-assembling deoxyribonucleic acid-programmed biological entities is possible. In the art TXTL systems are, for example, available for the cell-free synthesis of phages, including the phages T4, MS2, UX174 and T7 (Rustad et al., Synthetic Biology, 2018, 3(1): ysy002). Also reference is made to the cell-free production of therapeutic phages as described in Emslander et al., 2022, Cell Chemical Biology 29, 1-12.

[0022] In addition, bacterial cell lysates can be used instead or in addition to living bacterial cells. The use of cell lysates offers the advantage that phage propagation is not limited in time or space by the bacterial cells. For example, after infection with T4 phages the host E. coli cells is lysed after about 20 min. By contrast, no such lysis occurs in bacterial cell lysates and the only rate limiting factors of phage propagation in bacterial cell lysates is the building proteins in the lysates forming the phage particles.

[0023] With L-form bacteria, TXTL systems and bacterial cell lysates it is also possible to feed in new phage genomic DNA (that has been isolated or synthesized) during the phage propagation process or to exchange at least in part propagation medium or to add fresh propagation medium with new proteins that can form phage particles.

[0024] In accordance with step (a), item (i) of the method of the invention one or more nucleic acid molecules (preferably (an) expression vector(s)) encoding in expressible form the CRISPR-Cas nuclease as well as the guide RNA, and optionally the HDR template either directly (in the form a single-stranded or double-stranded DNA) or in expressible form encoded by a nucleic acid molecule (preferably an expression vector) are introduced into the bacterial cell, L-form bacterium TXTL system or bacterial cell lysate.

[0025] In accordance with step (a), item (ii) of the method of the invention the CRISPR-Cas nuclease itself (i.e. in proteinaceous form), the guide RNA itself (i.e, as RNA molecule), and in optionally the HDR template either directly or in expressible form encoded by a nucleic acid molecule are introduced into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate.

[0026] In accordance with step (a), item (iii) of the method of the invention the CRISPR-Cas nuclease itself (i.e. in proteinaceous form), as well as a nucleic acid molecule (preferably an expression vector) encoding in expressible form the guide RNA, and optionally the HDR template either directly (in the form a singlestranded or double-stranded DNA) or in expressible form encoded by a nucleic acid molecule (preferably an expression vector) are introduced into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate. In accordance with step (a), item (iv) of the method of the invention a nucleic acid molecule (preferably an expression vector) encoding in expressible form the CRISPR-Cas nuclease, as well as the guide RNA, and optionally the HDR template either directly (in the form a single-stranded or double-stranded DNA) or in expressible form encoded by a nucleic acid molecule (preferably an expression vector) are introduced into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate.

[0027] Finally, in accordance with step (a), item (iv) of the method of the invention the CRISPR-Cas nuclease and the guide RNA are introduced into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate in the form of a ribonucleoprotein complex (RNP) and optionally the HDR template either directly (in the form a single-stranded or double-stranded DNA) or in expressible form encoded by a nucleic acid molecule (preferably an expression vector). RNPs are assembled in vitro and can be delivered to the cell by methods known in the art, for example, electroporation or lipofection. RNPs are capable of cleaving the target site with comparable efficacy as nucleic acid-based (e.g. vector-based) CRISPR-Cas nucleases (Kim et al. (2014), Genome Research 24(6):1012-1019).

[0028] In the cases where the HDR template is in expressible form encoded by a nucleic acid molecule said nucleic acid molecule may be a separate nucleic acid molecule or the same nucleic acid molecule that encodes the CRISPR-Cas nuclease and / or the guide RNA. In the cases where the HDR template is directly introduced into the cell, the HDR template may be a linear double-stranded or single-stranded DNA molecule. The linear double-stranded DNA molecule is preferably a linearized PCR product and the linear single-stranded DNA molecule is preferably a single-stranded oligodeoxynucleotides (ssODN) as described herein above.

[0029] The nucleic acid molecules used in accordance with the present invention may be inserted into several commercially available vectors. Single vectors containing both the CRISPR-Cas nuclease and the gRNAs and optionally the HDR template are commercially available, thereby acting as an all-in-one vector. The method of the invention can alternatively be implemented by using two or three vectors containing the CRISPR-Cas nuclease, gRNA and the HDR template. It is also possible to use gRNA and / or HDR template-only vectors and to use cells in which the CRISPR-Cas nuclease has been integrated into the genome. The use of an all-in-one vector that expresses the gRNA, the CRISPR-Cas nuclease and optionally the HDR template is preferred since only one vector is to be introduced into the cells. A vector which can express the CRISPR-Cas nuclease and up to seven gRNAs is, for example, described in Sakuma et al, Sci Rep. 2014; 4: 5400.

[0030] Many single gRNA empty vectors (with and without the CRISPR-Cas nuclease) are available in the art. Likewise several empty multiplex gRNA vectors are available that can be used to express multiple gRNAs from a single plasmid (with or without the expression of the CRISPR-Cas nuclease). Finally, also vectors are available that only express the CRISPR-Cas nuclease (see https: / / www.addgene.org / crispr / empty-grna-vectors / ). Vector modification techniques are known in the art and, for example, described in Sambrook and Russel, 2001. Generally, vectors can contain one or more origins of replication (ori) and inheritance systems for cloning or expression, one or more markers for selection in the host, e.g., antibiotic resistance, and one or more expression cassettes. Suitable origins of replication include, for example, the Col E1 , the SV40 viral and the M 13 origins of replication. The nucleic acid sequences inserted in the vector can e.g. be synthesized by standard methods, or isolated from natural sources. Ligation of the coding sequences to transcriptional regulatory elements and / or to other amino acid encoding sequences can be carried out using established methods. Such regulatory sequences are well known to those skilled in the art and include, without being limiting, regulatory sequences ensuring the initiation of transcription, initiation of translation, internal ribosomal entry sites (IRES) or 2A linker (Owens, Proc. Natl. Acad. Sci. USA 98 (2001), 1471-1476) and optionally regulatory elements ensuring termination of transcription and stabilization of the transcript. Non-limiting examples for regulatory elements ensuring the initiation of transcription comprise a translation initiation codon, enhancers, insulators and / or promoters. Additional regulatory elements may include translational enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing, nucleotide sequences encoding secretion signals or, depending on the expression system used, signal sequences capable of directing the expressed polypeptide to a cellular compartment. Moreover, elements such as origin of replication, drug resistance gene, regulators (as part of an inducible promoter) may also be included.

[0031] Means and methods for the introduction for the nucleic acid molecule(s) expressing the CRISPR-Cas nuclease and / or the gRNAs and optionally (further) the HDR template into bacterial cells are known in the art and these methods encompass transducing or transforming cells.

[0032] Transformation is the process by which foreign DNA is introduced into a cell by a virus or viral vector into bacterial cells. In this respect it is noted that transfection is generally the process by which foreign DNA is introduced into a cell by a virus or viral vector into eukaryotic cells, but that term “transfection” is sometimes also used in the art in connection with bacterial systems, such as L-form bacteria; see, for example, Kilcher at al. Proc Natl Acad Sci U S A, 2018; 115(3):567-572. Transduction is a common tool used by molecular biologists to stably introduce a foreign gene into a bacterial host cell's genome. Generally, a plasmid is constructed in which the genes to be transferred are flanked by viral sequences that are used by viral proteins to recognize and package the viral genome into viral particles. This plasmid is inserted into a producer cell together with other plasmids (DNA constructs) that carry the viral genes required for formation of infectious virions. In these producer cells, the viral proteins expressed by these packaging constructs bind the sequences on the DNA / RNA (depending on the type of viral vector) to be transferred and inserted into viral particles. For safety, none of the plasmids used contains all the sequences required for virus formation, so that simultaneous transformation of multiple plasmids is required to get infectious virions. Moreover, only the plasmid carrying the sequences to be transferred contains signals that allow the genetic materials to be packaged in virions, so that none of the genes encoding viral proteins are packaged. Viruses collected from these cells are then applied to the cells to be altered. The initial stages of these infections mimic infection with natural viruses and lead to expression of the genes transferred and (in the case of lentivirus / retrovirus vectors) insertion of the DNA to be transferred into the cellular genome. However, since the transferred genetic material does not encode any of the viral genes, these infections do not generate new viruses (the viruses are "replicationdeficient"). In the present case transduction may be used to generate bacterial cells that comprise the CRISPR-Cas nuclease in their genome in expressible form.

[0033] Transformation is the process of deliberately introducing naked or purified nucleic acids or purified proteins or assembled ribonucleoprotein complexes into bacterial cells. Transformation is generally a non-viral based method, such as chemical transformation, electroporation, or sonoporation.

[0034] The practical chemical transformation approach to acquire competent cells is to make the bacterial cells artificially competent using chemicals. Chemical induction of competence generally involves the following steps: chilling the cells in the presence of a chemical, such as calcium phosphate to make them permeable incubation with DNA, heat shock treatment at 42 °C for 60-120 seconds that causes the DNA to enter the cells.

[0035] Sonoporation, or cellular sonication, is the use of sound in the ultrasonic range for increasing the permeability of the cell plasma membrane. Sonoporation uses high-intensity ultrasound to induce pore formation in cell membranes. This pore formation is attributed mainly to the cavitation of gas bubbles interacting with nearby cell membranes since it is enhanced by the addition of ultrasound contrast agent, a source of cavitation nuclei.

[0036] Transformation may also be a non-chemical method. Electroporation (gene electrotransfer) is a popular method, where transient increase in the permeability of cell membrane is achieved when the cells are exposed to short pulses of an intense electric field. Cell squeezing enables delivery of molecules into cells via cell membrane deformation. Optical transformation is a method where a tiny (~1 pm diameter) hole is transiently generated in the plasma membrane of a cell using a highly focused laser. Protoplast fusion is a technique in which transformed bacterial cells are treated with lysozyme in order to remove the cell wall. Following this, fusogenic agents (e.g., Sendai virus, PEG, electroporation) are used in order to fuse the protoplast carrying the gene of interest with the recipient target cell.

[0037] Finally, transformation may be a particle-based method. A direct approach to transformation is the gene gun, where the DNA is coupled to a nanoparticle of an inert solid (commonly gold), which is then "shot" (particle bombardment) directly into the target cell. Hence, the nucleic acid is delivered through membrane penetration at a high velocity, usually connected to microprojectiles. Magnetofection, or magnet-assisted transformation, is a transformation method that uses magnetic force to deliver DNA into target cells. Impalefection is carried out by impaling cells by elongated nanostructures and arrays of such nanostructures such as carbon nanofibers or silicon nanowires which have been functionalized with plasmid DNA.

[0038] Means for introducing proteins (or peptides) into living cells are known in the art and comprise but are not limited to microinjection, electroporation, lipofection (using liposomes), nanoparticle-based delivery, and protein transduction. Any one of these methods may be used in connection with step (a’). In this regard, the CRISPR-Cas nuclease to be introduced may either be isolated from their natural environment or recombinantly produced.

[0039] A liposome used for lipofection is a small vesicle, composed of the same material as a cell membrane (i.e., normally a lipid bilayer e.g. made of phospholipids), which can be filled with one or more protein(s) (e.g. Torchilin VP. (2006), Adv Drug Deliv Rev., 58(14):1532-55). To deliver a protein into a cell, the lipid bilayer of the liposome can fuse with the lipid bilayer of the cell membrane, thereby delivering the contained protein into the cell. It is preferred that the liposomes used in accordance with invention are composed of cationic lipids. The cationic liposome strategy has been applied successfully to protein delivery (Zelphati et al. (2001). J. Biol. Chem. 276, 35103-35110). As known in the art, the exact composition and / or mixture of cationic lipids used can be altered, depending upon the protein(s) of interest and the cell type used (Feigner et al. (1994). J. Biol. Chem. 269, 2550-2561). Nanoparticlebased delivery of Cas9 ribonucleoprotein and donor DNA for the induction of homology-directed DNA repair is, for example, described in Lee et al. (2017), Nature Biomedical Engineering, 1 :889-90.

[0040] Protein transduction specifies the internalisation of proteins into the cell from the external environment (Ford et al (2001), Gene Therapy, 8:1-4). This method relies on the inherent property of a small number of proteins and peptides (preferably 10 to 16 amino acids long) being able to penetrate the cell membrane. The transducing property of these molecules can be conferred upon proteins which are expressed as fusions with them and thus offer, for example, an alternative to gene therapy for the delivery of therapeutic proteins into target cells. Commonly used proteins or peptides being able to penetrate the cell membrane are, for example; the antennapedia peptide, the herpes simplex virus VP22 protein, HIV TAT protein transduction domain, peptides derived from neurotransmitters or hormones, or a 9xArg-tag.

[0041] Microinjection and electroporation are well known in the art and the skilled person knows how to perform these methods. Microinjection refers to the process of using a glass micropipette to introduce substances at a microscopic or borderline macroscopic level into a single living cell. Electroporation is a significant increase in the electrical conductivity and permeability of the cell plasma membrane caused by an externally applied electrical field. By increasing permeability, protein (or peptides or nucleic acid sequences) can be introduced into the living cell.

[0042] The CRISPR-Cas nuclease may be introduced into the bacterial cells as an active enzyme or as a proenzyme. In the latter case the CRISPR-Cas nuclease is biochemically changed within the cells (for example by a hydrolysis reaction revealing the active site, or changing the configuration to reveal the active site), so that the proenzyme becomes an active enzyme.

[0043] The term “in expressible form” means that the one or more nucleic acid molecules may encode their constituents in a form that ensures that the guide RNAs and / or the HDR template (if being encoded) are transcribed and that the CRISPR-Cas nuclease (if being encoded) is transcribed and translated into the active enzyme in the cells.

[0044] The Tet family of dioxygenases is widely distributed across the tree of life, including in the heterolobosean amoeboflagellate Naegleria gruberi. Tet-like proteins include homologues of the mammalian Like mammalian Tet proteins, such as NgTetl (Naegleria Tet-like protein). Tet-like proteins acts on 5-methyl cytosine (5mdC) and generates 5-hydroxymethylcytosine (5hmdC), 5-formylcytosine (5fdC) and 5-carboxylcytosine (5cadC). NgTetl shares significant sequence conservation (approximately 14% identity or 39% similarity) with mammalian Tet1 .

[0045] Naegleria gruberi is a species of Naegleria. Naegleria gruberi is a eukaryotic free-living organism that can be extracted from wet soil and freshwater. The strain NEG-M is the only Naegleria species that has a fully sequenced genome. Naegleria belongs to the Jakobids, Euglenozoans, and Heteroloboseans (JEH) group.

[0046] As is illustrated in Figure 1A the Tet-like protein transforms 5-methyl deoxycytosine (5mdC) via 5- hydroxymethyl-2’-deoxycytosine (5hmdC) and 5-Formyl-2'-deoxycytidine (5fdC) to and 5-carboxy-2'- deoxycytosine (5cadC). Hence, in the method of the invention the Tet-like protein prevents or blocks the generation of 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC) in the genomic DNA of the phages because the precursor of 5ghmdC is no longer formed, thereby preventing these bulky nucleotides and in particular the sugar from 5-a- / p-glycosyl. It is believed that these bulky nucleotides and in particular the sugar from 5-a- / p-glycosyl are at least one of the reasons why CRISPR-Cas nuclease fail to efficiently introduce DSBs at the target site of the phage genome. In this respect it is of note that phages evolutionary developed various defence mechanisms that allow them to replicate in the host despite the defence systems of the host cells, such as enzymes that are to degenerate foreign DNA. The bulky nucleotides and in particular the sugar from 5-a- / p-glycosyl are such a defence mechanism of the phages and they interfere with the cutting efficiency of the CRISPR-Cas nuclease. It is surprisingly demonstrated herein that this bottleneck of lack of cutting efficiency can be overcome by enzymatic activity of the Tet-like protein and that this solves the long-existing, above discussed problem of the prior art.

[0047] Unlike in E. coll, in eukaryotes, several enzymes are involved in cytosine metabolism, as this is a critical epigenetic regulatory mechanism of eukaryotic gene expression (Zemach, McDaniel et al. 2010). Ten- eleven translocation methylcytosine dioxygenases (shortly TET enzymes) are involved in active DNA demethylation via iterative oxidation of 5-methyl-2 '-deoxycytosine (5mdC) to 5hmdC, 5-formyl-2'- deoxycytosine (5fdC), and 5-carboxy-2 '-deoxycytosine (5cadC) (Tahiliani, Koh et al. 2009, Ito, DAIessio et al. 2010). The catalytic potential of TET enzymes was already applied in epigenetics research, particularly for the mapping of 5mdC sites via bisulfite sequencing (Yu, Hon et al. 2012).

[0048] CRISPR-Cas has emerged as a powerful tool for precise genome editing in diverse organisms and recently in bacteriophages. The technique is frequently used to study protein function by the generation of inactive mutants via the introduction of point mutations. However, in the context of phage engineering a low editing efficiency remains a major bottleneck for the optimal application of CRISPR-Cas technique. For some of the phages, including the model phage T4, the low editing efficiency is a consequence of viral DNA hypermodifications.

[0049] By the present invention the bottleneck for the optimal application of CRISPR-Cas technique to phages genomes has been overcome by the innovative approach to enhance the efficiency of CRISPR-Cas editing in phages by utilizing the eukaryotic enzyme Tet-like protein. While this has been exemplified for T4 phage and the Tet1 -like dioxygenase from Naegleria gruberi (NgTET) the innovative approach also works with other phages carrying cytosine hypermodfications and / or Tet-like proteins.

[0050] In was found that Tet-like protein facilitates the reduction of sterically demanding cytosine modifications within the phage genome for one viral generation, resulting in increased accessibility of the target sites to the Cas nuclease. Thereby the Cas nuclease can cut the phage genome significantly more efficiently. The results in the appended examples show a strong improvement in Cas-mediated T4 DNA cleavage in vivo, resulting in a substantial increase of the mutagenesis rate. Specifically, it is demonstrated in the appended examples that the overexpression of the NgTET enzyme in E. coli significantly reduces the abundance of bulky 5ghmdC in the T4 genome, allowing more efficient site-specific targeting of the viral DNA by Cas12 and Cas9 nucleases.

[0051] In this connection, it is emphasized that the Tet-like protein is only found in eukaryotic cells. In the innovative approach as provided herein, this eukaryotic enzyme is expressed in a bacterial cell (or L- form bacterium or bacterial lysate or bacterial TXTL) and acts on the genome of a virus. It was not foreseeable whether the eukaryotic enzyme is active in this environment and in particular whether this single enzyme is sufficient to reduce the abundance of the cytosine hypermodifications from the phage genome in the bacterial context thereby enhancing the cutting by Cas nucleases. As discussed above, in eukaryotes several enzymes are involved in cytosine metabolism. In this connection it is emphasized that the Tet-like protein needs to exert its enzymatic activity rapidly, in view of the T4 phage life circle of only 20min, It was also not foreseeable that the eukaryotic enzyme can reduce the abundance of the cytosine hypermodifications from the phage genome in this short time frame.

[0052] It is also emphasized that after the desired genome editing event by CRISPR-Cas, the removal of the cytosine hypermodifications it fully reversible by simply growing the genome-edited phages for at least one generation in the absence of the Tet-like protein. Als shown in the examples, the mutagenesis, the modification pattern of T4 DNA can be completely restored by infection of wild-type E. coli. This reversibility is a further advantage of the innovative approach as presented herein.

[0053] In accordance with preferred embodiment of the first aspect of the invention, the method further comprises prior to step (a) (a-a) introducing into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate a nucleic acid molecule encoding in expressible form a Tet-like protein, and / or (a-b) introducing into the bacterial cell, TXTL system or bacterial cell lysate the phages the genome of which is to be genetically engineered.

[0054] Also the nucleic acid molecule encoding in expressible form a Tet-like protein is preferably a vector as discussed herein above. With respect to the step of introducing the phages into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate, it is to be understood that in the case of a bacterial cell the phages are generally and preferably introduced into the bacterial cell by infecting the bacterial cell with the phages. The TXTL system is cell free and the bacterial cell lysate does not comprise intact cells. Hence, the phage DNA can be introduced to the TXTL system or the bacterial cell lysate by adding them to the TXTL system or the bacterial cell lysate.

[0055] In accordance with a more preferred embodiment of the first aspect of the invention the method further comprises prior to step (a-b) the steps of (a-c) propagating the phages the genome of which is to be genetically engineered in a bacterial cell, L-form bacterium, TXTL system or a bacterial cell lysate expressing a Tet-like protein, and (a-d) isolating the propagated phages and employing the propagated phages in step (a-b).

[0056] As discussed herein above, the Tet-like protein prevents the formation of 5ghmdC in the genomic DNA of the phages, thereby reducing the appearance in the phage genome these bulky nucleotides from the phage genome which leads to a marked increase of the cutting efficiency of the CRISPR-Cas nuclease. It is to be understood that step (a-b) of the above preferred embodiment is carried out in the absence the CRISPR-Cas nuclease. Hence, step (a-b) is an additional step that is just to modify the phage DNA before the genome editing event with the aim to make it even more prone for the DSB at the target site.

[0057] The propagated phages can be isolated by means that are known in the art, such as simple removal of bacterial debris by filtration and / or centrifugation.

[0058] The propagation of phages in a TXTL system is, for example, described in Rustad et al. (2018); Synthetic Biology, 3(1):ysy002. Moreover, the synthesis of T4 phages in a TXTL reaction as well as the sythehis of the NgTET dioxygenase within the same system TXTL are illustrated in Example 4. For instance, the inventors of the present application propagated T4 and T7 phages in a TXTL system up to titer of 1 O10PFU / ml.

[0059] In accordance with preferred embodiment of the first aspect of the invention wherein a nucleic acid molecule comprises, consists of, or encodes a donor template with homology to the target locus is used, the method further comprises (c) isolating the phages after step (b), and (d) introducing into the bacterial cell, the L-form bacterium, the TXTL system or the bacterial cell lysate expressing a Tet-like protein, a CRISPR-Cas nuclease, and a guide RNA comprising (i) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (ii) a second segment that interacts with the CRISPR-Cas nuclease of (i), thereby enriching the phages that have been genetically engineered by homology directed repair (HDR). The additional genome editing step (in particular a counterselection step) of this preferred embodiment is carried out after the initial genome editing step (b) of the method of the invention and results in enriching the phages that have been genetically engineered by HDR. In this additional step a CRISPR- Cas nuclease and a guide RNA are used by no donor template is used.

[0060] This is because the incorporation of the donor template after HDR modifies the target site by genetic engineering, so that the CRISPR-Cas nuclease can no longer be guided by the guide RNA to the target site in the phage genome since the target site can no longer be found. On the other hand, in the phages that underwent DSB repair by NHEJ instead of the desired HDR the DSB repair by NHEJ may be error- free. In these phages the target site can still be found and DSBs can therefore still be introduced by CRISPR-Cas nuclease at the target site. Since not all DSBs are successfully repaired of the additional genome editing step of the above preferred embodiment enriches the phages that have been genetically engineered by HDR.

[0061] On order to further improve the selection efficiency it is preferred that the donor template comprises a mutated PAM sequence. This further ensures that the HDR modified phage genome is not cut by the CRISPR-Cas nuclease.

[0062] In accordance with a further preferred embodiment of the first aspect of the invention the method further comprises (e) isolating the phages after step (b) or (d), and (f) separating the phages from each other in order to obtain separated phages, preferably by introducing them into bacterial cells, L-form bacterium, TXTL systems or bacterial cell lysates and plating them out, by fluorescent activated cell sorting, microfluidics or by a dilution series.

[0063] As discussed above and as is also evident from the appended examples in case of genetic engineering by CRISPR-Cas nucleases not all phages are genetically engineered as desired. In the case of the absence of a donor template the DSBs can be repaired by NHEJ which is error-prone, so that it might be desired to obtain a phage with error-free NHEJ. In the case of the presence of a donor template the DSBs can be repaired by NHEJ or HDR, so that it might be desired to obtain a phage with HDR.

[0064] In connection with the selection of such desired phages it might be desired to separate the phages from each other in order to obtain separated phages than can then be checked subsequently for the desired phages.

[0065] Non-limiting but preferred examples to obtain separated phages are introducing them into bacterial cells, L-form bacteria, TXTL systems or bacterial cell lysates and plating them out (e.g. on an agar plate), by fluorescent activated cell sorting, microfluidics or by a dilution series.

[0066] For plating out, for example, increasing dilutions of phage filtrate can be mixed with bacteria and placed on plate surface by spreading or soft agar overlay. After incubation, the plate is checked for the appearance of plaques. Also for plating out, for example, a plate can be inoculated with host bacteria to form a lawn, then small drops of phage filtrate are placed on the surface. After incubation, a zone of lysis indicates the presence of phage.

[0067] For a dilution series, for example, phage lysates are diluted to the point of producing just less than confluent lysis on a plate.

[0068] Fluorescence-activated cell sorting (FACS), sometimes called fluorescence-assisted cell sorting, is a specialized type of flow cytometry that uses fluorescent markers to target and isolate cell groups. Fluorescent activated cell sorting for phage isolation is, for example, described in Melo et al., Antibiotics (Basel). 2022 Feb; 11 (2): 164. The term microfluidics covers methods that deal with the rapid and efficient manipulation of small quantities of fluids (pL or below). For example, the present inventors’ research uses microfluidic structures to mix liquids or to generate well-defined, identically sized droplets (oil I water). Microfluidics for phage isolation is, for example, described in Mabrouk et al. (2023), ASM Journals, Applied and Environmental Microbiology, Vol. 89, No. 1.

[0069] In accordance with a more preferred embodiment of the first aspect, wherein a nucleic acid molecule comprises, consists of, or encodes a donor template with homology to the target locus is used, the method further comprises (g) amplifying the target locus of the separated phages by primers pairs being labeled with primer pair-specific barcodes, and (h) sequencing the amplification product of (g) thereby identifying the phages wherein the target locus has been genetically engineered by the donor template.

[0070] In accordance with an even more preferred embodiment of the first aspect the sequencing is high- throughput sequencing and / or next-generation sequencing, more preferably is nanopore sequencing.

[0071] Steps (g) and (h) can determine whether and, if yes, which of the separated phages carries the desired genome editing. In the case of an HDR genome-edited phage the target site has been modified by the donor template and the primers are either specific for the HDR genome-edited target locus (e.g. in the case of a small modification such as a gene insertion) or amplify a sequence including the HDR genome- edited edited target locus (e.g. in the case of a small modification such as an SNP).

[0072] The primer pair-specific barcodes can then be used in order to identify the amplification products from the different separated phages by sequencing the amplification product, thereby indicating which of the separated phages carries the desired genome editing. This sequencing is preferably high-throughput sequencing and / or next-generation sequencing, most preferably is nanopore sequencing (also known as Oxford NanoPore sequencing).

[0073] An Oxford NanoPore (ONP)-based screening approach to efficiently screen for T4 phage mutants with primer pair-specific barcodes and without introducing any additional reporter proteins or tags to the viral genome is provided herein. By this screening approach, even point mutations can be easily identified, which is difficult to achieve with other efficient phage mutant counter-selection approaches (Adler, Hessler et al. 2022). The combination of the facilitated mutagenesis of T4 phage and efficient screening allow the generation of point mutations in T4 DNA that can be used to study the role of specific T4 genes and proteins. Hence, primer pair-specific barcodes are particularly helpful in the context of the above more preferred embodiment.

[0074] In accordance with a further preferred embodiment of the first aspect of the invention, the method further comprises (k) propagating the phages the genome of which has been genetically engineered in a bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate that does not express a Tet-like protein, thereby restoring 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC) in the genomic DNA.

[0075] As discussed herein above, the removal of the cytosine hypermodfications from the genome of phages by a Tet-like protein for the genome editing event is fully reversible by simply growing the genome-edited phases for at least one generation in the absence of the Tet-like protein. The additional step (k) of the above preferred embodiment restores the “wild-type” cytosine hypermodifications in the phage genome after the desired genome editing thereby leading to phages that are only distinguished from the phages before genome editing by the desired genome editing. This reversibility is a further advantage of the innovative approach as presented herein.

[0076] The present invention relates in a second aspect to a bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate expressing a Tet-like protein and comprising a phage.

[0077] The definitions and preferred embodiments of the first aspect of the invention apply mutatis mutandis to the second aspect of the invention as are as being amenable for combination with the second aspect.

[0078] To the best knowledge of the inventors such a bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate is not known in the prior art. This is because the expression of a Tet-like protein in a bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate comprising a phage only makes technical sense based on the surprising finding as demonstrated herein that the Tet-like protein can modify the genome of the phage, so that the phage genome becomes significantly more amendable for genomeediting by a CRSPR-Cas nuclease.

[0079] In accordance with a preferred embodiment of the second aspect of the invention the bacterial cell, L- form bacterium, TXTL system or bacterial cell lysate further comprises (i) a CRISPR-Cas nuclease, and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and (iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus.

[0080] The CRISPR-Cas nuclease and the guide RNA are required in order to introduce an DSB at the target site in the phage genome. As discussed above the DSB can be repaired by NHEJ and in the presence of the donor template also by HDR. The present invention relates in a third aspect to a kit for genetically engineering the genome of phages at a target locus comprising (A) one or more nucleic acid molecules, said one or more nucleic acid molecules encoding in expressible form (i) a CRISPR-Cas nuclease, (ii) optionally a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i) or a cloning site for the addition of said guide RNA into the one or more nucleic acid molecules, and (iii) optionally a donor template with homology to the target locus or a cloning site for the addition of said donor template into the one or more nucleic acid molecules, and (B) a nucleic acid molecule encoding in expressible form a Tet-like protein.

[0081] The definitions and preferred embodiments of the first and second aspect of the invention apply mutatis mutandis to the third aspect of the invention as are as being amenable for combination with the third aspect. For example also in connection with the third aspect the nucleic acid molecules are preferably expression vectors.

[0082] The above kit necessarily comprises a nucleic acid molecule encoding in expressible from a CRISPR- Cas nuclease and nucleic acid molecule encoding in expressible form a Tet-like protein, because a CRISPR-Cas nuclease and a Tet-like protein are the components that are required in order to genetically engineering the genome of phages with high efficiency at any desired target locus and this combination of proteins was unknown in the art.

[0083] The kit optionally comprises one or more nucleic acid molecules encoding in expressible from a guide RNA and / or a donor template. This is because the guide RNA and the donor template are different for every target locus; i.e. they have to be designed based on the desired target locus and / or genetic modification.

[0084] Hence, the kit also optionally comprises one or more cloning sites for the addition of a guide RNA and / or a donor template into the one or more nucleic acid molecules. This cloning site can then be employed in order to easily supplement the kit so that it can be used to edit the phage genome at the desired target locus and / or genetic modification.

[0085] The various components of the kit may be packaged into one or more containers such as one or more vials. The vials may, in addition to the components, comprise preservatives or buffers for storage. The kit may comprise instructions how to use the kit, which preferably inform how to use the components of the kit for genetically engineering the genome of phages at a target locus.

[0086] In accordance with a preferred embodiment of the third aspect of the invention, the kit further comprises a nucleic acid molecule comprising or consisting of phage DNA, preferably T4 phage DNA. This nucleic acid molecule can serve as a positive control for checking the enzymatic activity of the CRISPR-Cas nuclease to cut at the target site along with the guide RNA. The nucleic acid molecule may be genomic phage DNA, Tet-like protein treated genomic phage DNA, or a nucleic acid molecule that has been synthesized but is identical to at least a part of the phage genome.

[0087] In accordance with a preferred embodiment of all aspects of the invention, the Tet-like protein comprises of consists of (a) the amino caid sequence of SEQ ID NO: 1 , (b) the amino acid sequence being encoded by SEQ ID NO: 2, or (c) an amino acid sequence being at least 80%, preferably at least 90% and most preferably at least 95% identical to the amino acid sequence of (a) or (b).

[0088] The amino acid sequence of SEQ ID NO: 1 is and the nucleotide sequence of SEQ ID NO: 2 encodes the NgTET dioxygenase as used in the appended examples.

[0089] NgTET protein sequence (SEQ ID NO: 1)

[0090] MGTTFKQQTIKEKETKRKYCIKGTTANLTQTHPNGPVCVNRGEEVANTTTLLDSGGGINKKSLLQNLL SKCKTTFQQSFTNANITLKDEKWLKNVRTAYFVCDHDGSVELAYLPNVLPKELVEEFTEKFESIQTGR KKDTGYSGILDNSMPFNYVTADLSQELGQYLSEIVNPQINYYISKLLTCVSSRTINYLVSLNDSYYALNN CLYPSTAFNSLKPSNDGHRIRKPHKDNLDITPSSLFYFGNFQNTEGYLELTDKNCKVFVQPGDVLFFK GNEYKHVVANITSGWRIGLVYFAHKGSKTKPYYEDTQKNSLKIHKETK

[0091] NgTET gene sequence (SEQ ID NO: 2) atgggaacgacatttaaacagcagacgattaaagaaaaagagacaaagcgtaaatactgtatcaaagggaccactgcgaatctgacacaa acccatcccaatgggccagtgtgtgttaaccgcggggaggaagtagcaaatacgactactctgttggactcagggggcgggattaacaaaaa atcgctgttgcagaatctgttgtccaaatgtaaaactacatttcagcagtcatttacaaacgccaacattactttaaaggatgaaaagtggcttaaa aacgtccgtactgcttattttgtttgcgatcatgacgggagcgtcgaacttgcataccttcctaacgtgcttcccaaagaattagtcgaagaattcac cgagaaatttgaatcgatccagaccggacgtaagaaagacacaggttactcaggtattctggacaactcgatgccgttcaattacgtcactgcg gatttatcacaggagttaggacagtatctgtctgagattgtgaatcctcagatcaactattacatcagtaaattgctgacttgcgttagttcacgtaca atcaattacctggtatctttgaatgactcgtactatgcccttaacaactgtttgtatccttcaaccgccttcaactcattaaagccgtccaacgacggc caccgcatccgtaaacctcataaggacaatttggacattaccccgtcgagccttttctattttggaaattttcaaaatacggaaggatatcttgagtt aacagacaagaattgcaaagttttcgtccaaccgggggatgtattatttttcaaaggcaatgaatataaacacgtcgtggccaatatcacctcgg gctggcgcattggattggtctacttcgcacacaaggggagtaaaactaaaccgtattatgaagacacgcagaagaactccctgaaaattcata aagaaacgaaataa

[0092] In accordance with the present invention, the term “percent (%) sequence identity” describes the number of matches (“hits”) of identical nucleotides / amino acids of two or more aligned nucleic acid or amino acid sequences as compared to the number of nucleotides or amino acid residues making up the overall length of the template nucleic acid or amino acid sequences. In otherterms, using an alignment, fortwo or more sequences or subsequences the percentage of amino acid residues or nucleotides that are the same (e.g. 80%, 85%, 90% or 95% identity) may be determined, when the (sub)sequences are compared and aligned for maximum correspondence over a window of comparison, or over a designated region as measured using a sequence comparison algorithm as known in the art, or when manually aligned and visually inspected. This definition also applies to the complement of any sequence to be aligned.

[0093] Nucleotide and amino acid sequence analysis and alignment in connection with the present invention are preferably carried out using the NCBI BLAST algorithm (Stephen F. Altschul, Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), Nucleic Acids Res. 25:3389-3402). BLAST can be used for nucleotide sequences (nucleotide BLAST) and amino acid sequences (protein BLAST). The skilled person is aware of additional suitable programs to align nucleic acid sequences.

[0094] The sequence identity of at least at least 95% is with increasing preference at least 96%, at least 97%, at least 98% and at least 99% identity.

[0095] In accordance with another preferred embodiment of all aspects of the invention the phages prior to the contact with a Tet-like protein are characterized by genomic DNA with 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC).

[0096] While it is believed that the genome of a vast number of different phage species and families is characterized by genomic DNA with 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC), this might not be case for all phage species and families.

[0097] Hence, the preferred embodiment ensures that the phage genome to be genetically engineering is characterized by genomic DNA with 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), that can then be removed by the enzymatic activity of the Tet-like protein. In addition and as discussed above, the formation of 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC) is prevented.

[0098] Whether the genome of a phage is characterized by genomic DNA with 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC) can be determined in straight forward manner by blasting the genome of phages with the sequences encoding the methyltransferase for adding 5mdC, deoxycytidylate 5- hydroxymethyltransferase and / or the glycosyltransferase of the T4 phage.

[0099] Deoxycytidylate 5-hydroxymethyltransferase (EC 2.1.2.8) is an enzyme that catalyzes the chemical reaction 5,10-methylenetetrahydrofolate + H2O + deoxycytidylate tetrahydrofolate + 5- hydroxymethyldeoxycytidylate. The 5-hydroxymethyltransferase is required for obtaining 5hmdC from 5mdC. The glycosyltransferase is required for transferring the glycosyltransferase a- / p-glycosyl to 5hmdC in order to form 5ghmdC.

[0100] Hence, in case sequences being orthologous to the sequences encoding the deoxycytidylate 5- hydroxymethyltransferase and / or the glycosyltransferase of the T4 phage can be found in a phage genome that is to be modified the phage to be modified genome can be safely assumed to be characterized by genomic DNA with 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC).

[0101] Many phage genomes have already been sequenced and are available in data bases. In addition, phage genomes are small with a known size range between about 3.330 nucleotides (RNA viruses of Escherichia coli) and almost 500 kbp (Bacillus megaterium phage G). Hence, yet unknown phage genome can be sequenced in short time, if necessary.

[0102] In accordance with a further preferred embodiment of all aspects of the invention, the phages are members of the family of Myoviridae, preferably members of the subfamily Tevenvirinae, are most preferably Tequatroviruses, and most preferably are T4 phages.

[0103] T4 phages are used in the appended examples. Their genome is characterized by genomic DNA with one or more 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC). T4 phages belong to the family of Myoviridae, the subfamily Tevenvirinae and are a type of Tequatroviruses.

[0104] In accordance with a further preferred embodiment of all aspects of the invention, the bacterial cell, L- form bacterium, TXTL system or bacterial cell lysate is or is derived from a Gram-negative cell, preferably from the order Enterobacterales, more preferably from the family of Enterobacteriaceae and is most preferably an E. coli cell or are derived therefrom.

[0105] Phages are generally host cell specific and are therefore only capable of infecting certain types of bacteria. The T4 phage generally infects E. coli and related Shigella species. E. coli and Shigella species are Gram-negative bacteria of the order Enterobacterales and the family of Enterobacteriaceae.

[0106] In accordance with a still further preferred embodiment of all aspects of the invention, the CRISPR-Cas nuclease is a Class 2, Type II or a Class 2, Type V CRISPR / Cas nuclease, is preferably Cas9 or Cas12 and is most preferably Cas12.

[0107] In the examples herein below, Cas9 and Cas12 were booth employed. The action of the Tet-like protein significantly increased the CRISPR-Cas nuclease cleavage efficiency for both CRISPR-Cas nucleases to about 50-75% (depending on the selected guide RNA). In the absence of the Tet-like protein and with Cas12 no positive HDR-modified mutants out of 48 mutants were found in the examples while in the presence of the Tet-like protein and Cas12 about ~4% HDR-modified mutants were obtained. This finding was in particular surprising in view of Vlot et al., Nucleic Acids Research, 2018, Vol. 46, No. 2 873-885, wherein it is reported that DNA glucosylation of phages by Cas12 is not impaired in binding and cleavage of glucosylated target DNA. It is of further note in this respect that Vlot et al, observed this in vitro while the appended examples provide in vivo results.

[0108] Cas9 and Cas12 are Class 2, Type II or Class 2, Type V CRISPR / Cas nucleases. Cas9 is the first and best-characterized CRISPR-Cas nuclease. Cas9 makes a blunt double-stranded DNA break. Cas12 (CRISPR associated protein 12, also known as Cpf1 or Cas12a) is an RNA-guided endonuclease that forms part of the CRISPR system in some bacteria and is used by scientists to modify DNA. Cas12 is distinguished from Cas9 by being smaller and simpler, not requiring a tracrRNA, and creating sticky rather than blunt ends at the cut site.

[0109] Regarding the embodiments characterized in this specification, in particular in the claims, it is intended that each embodiment mentioned in a dependent claim is combined with each embodiment of each claim (independent or dependent) said dependent claim depends from. For example, in case of an independent claim 1 reciting 3 alternatives A, B and C, a dependent claim 2 reciting 3 alternatives D, E and F and a claim 3 depending from claims 1 and 2 and reciting 3 alternatives G, H and I, it is to be understood that the specification unambiguously discloses embodiments corresponding to combinations A, D, G; A, D, H; A, D, I; A, E, G; A, E, H; A, E, I; A, F, G; A, F, H; A, F, I; B, D, G; B, D, H; B, D, I; B, E, G; B, E, H; B, E, I; B, F, G; B, F, H; B, F, I; C, D, G; C, D, H; C, D, I; C, E, G; C, E, H; C, E, I; C, F, G; C, F, H; C, F, I, unless specifically mentioned otherwise.

[0110] Similarly, and also in those cases where independent and / or dependent claims do not recite alternatives, it is understood that if dependent claims refer back to a plurality of preceding claims, any combination of subject-matter covered thereby is considered to be explicitly disclosed. For example, in case of an independent claim 1 , a dependent claim 2 referring back to claim 1 , and a dependent claim 3 referring back to both claims 2 and 1 , it follows that the combination of the subject-matter of claims 3 and 1 is clearly and unambiguously disclosed as is the combination of the subject-matter of claims 3, 2 and 1 . In case a further dependent claim 4 is present which refers to any one of claims 1 to 3, it follows that the combination of the subject-matter of claims 4 and 1 , of claims 4, 2 and 1 , of claims 4, 3 and 1 , as well as of claims 4, 3, 2 and 1 is clearly and unambiguously disclosed.

[0111] The above considerations apply mutatis mutandis to all appended claims.

[0112] The figures show:

[0113] Figure 1 - Hypermodifications within T4 DNA. A: The cytosines in T4 phage DNA are extensively hypermodified to 5ghmdC by T4-originating enzymes. The intermediate of the modification, 5hmdC, is known to be both a substrate and a product for the eukaryotic NgTET dioxygenase. Based on this, the glycosylation of 5hmdC by a-gt / p-gt to 5ghmdC is expected to be downregulated in the presence of NgTET, as the latter would oxidize 5hmdC to 5fdC and 5cadC. B-E: LC-MS analysis of the composition. F-J: Relative abundance (%) of 2'-deoxycytidine metabolites determined via LC-MS analysis in different T4 strains: T4 WT, T4 WT propagated in the presence of empty vector (EV) (T4 WT EV), NgTET-treated T4, NgTET D234A-treated T4, and recovery T4. The presence of dC traces in recovery T4 DNA may be attributed to residual NgTET-treated T4 phages that did not infect E. coli and therefore were not recovered. Hashtag highlights the nucleosides not detected in a sample, n = 3 biological replicates.

[0114] Figure 2 - Determination of the effect of NgTET overexpression on CRISPR-Cas activity in vivo. A: Target mutations in alt and modA genes that lead to the depletion of ADP-ribosylation activity. B: Design of experiment and results of the efficiency of plating (EOP) experiment in the presence or absence of NgTET / NgTET D234A (n=3). C: Design of experiment and results of lysis assay of E. coli overexpressing Cas12 targeting alt in the presence and absence of NgTET. Here, the efficiencies of lysis by T4 WT and NgTET T4 phages are compared (n=3).

[0115] Figure 3 - Established workflow for T4 phage mutagenesis and mutants screening.

[0116] Figure 4 - TXTL of bacteriophage T4. a. Schematic representation of a TXTL reaction, b. Plaque assay of a TXTL (1 nM T4 WT DNA).

[0117] The Examples illustrate the invention:

[0118] Example 1 - Overexpression of NgTET in E. coli reduces the abundance of sterically demanding 5ghmdC modification within T4 DNA

[0119] Eukaryotic TET dioxygenases efficiently oxidize 5mdC metabolites in their respective organisms. Therefore, we hypothesized that their activity could be harnessed to alter the cytosine modification pattern of T4 phage DNA in vivo. Specifically, we aimed to heterologously overexpress an active TET enzyme in E. coli during T4 phage infection to compete with T4 phage a / p-gt enzymes for substrate 5hmdC and to oxidize it to 5fdC and 5cadC (Figure 1A), thereby reducing the overall abundance of 5ghmdC modifications in T4 DNA.

[0120] To test this hypothesis, we cloned the NgTET enzyme from the single-cell protest Naegleria gruberi into E. coli (Hashimoto, Pais et al. 2014). The newly generated strain overexpressing NgTET was exposed to a T4 phage infection. The DNA composition of the progeny phage (NgTET T4 DNA) was analyzed by LC-MS (Figure 1 B) and compared to wild-type T4 DNA (WT T4 DNA) (Figures 1 C and 1 D). NgTET T4 DNA contained the NgTET oxidation products of 5hmdC, namely 5fmC and 5cadC, confirming the activity of dioxygenase on T4 DNA.

[0121] Since the alteration of the cytosine modification pattern was based on the activity of NgTET enzyme during the phage replication process in E. coli, we hypothesized that infecting wild-type E. coli with T4 phage containing altered DNA would result in a restored abundance of the T4 DNA hypermodifications in the next viral generation. This assumption was experimentally confirmed, demonstrating complete recovery of cytosine modifications in the next phage generation (Figure 1 E).

[0122] To exclude the possibility that the altered cytosine modification pattern was due to NgTET enzymatic activity, rather than its overexpression and interaction with DNA, we generated a NgTET D234A mutant. The residue D234 is known to be important for the preference of C5-modified cytosines as a substrate for NgTET (Hashimoto, Pais et al. 2015). We tested the activity of NgTET D234A on methylated DNA and proved the abolishment of the enzymatic activity due to point mutation. We then tested the mutant for in vivo activity on T4 DNA during the infection. The LC-MS analysis has proved no effect of NgTET D234A on the T4 DNA modifications abundance (Figure 1 D).

[0123] In summary, NgTET can alter the abundance and ratio of hypermodifications in T4 DNA, particularly by reducing the abundance of sterically demanding 5ghmdC. The changes were unambiguously linked to NgTET activity by generating its inactive version NgTET D234A which showed no effect on the T4 DNA modifications level. Furthermore, the wild-type-like epigenetic pattern of T4 DNA can be completely restored for NgTET T4 DNA by infection of wild-type E. coli strain.

[0124] Example 2 - Overexpression of NgTET facilitates Cas-mediated cleavage on T4 DNA

[0125] As a model for our mutagenesis study, we selected the two T4 phage-originating ADP- ribosyltransferases, Alt and ModA, known to play an important role in E.coli control take-over by T4 phage but whose exact mechanisms remain unclear. We aimed to generate T4 phage variants carrying inactive versions of both proteins by exchanging single amino acids essential for their activity. Therefore, we selected conserved residues for mutagenesis and verification of catalytic activity in vitro (Tiemann, Depping et al. 2004). The Alt E577A and ModA E165A mutations have caused the complete abolishment of ADP-ribosylation activity, making these residues to targets of the mutagenesis (Figure 2A).

[0126] To generate T4 phages harboring these mutations, we employed the CRISPR-Cas systems 9 and 12, which were previously applied for T4 mutagenesis. The spacers were designed to target the region of mutation insertion. We determined the efficiency of plating (EOP) for each construct after infecting E. coli cells expressing respective CRISPR-Cas systems with T4 phage (Figure 2B). The high EOP corresponds to low Cas activity with a selected spacer. Most constructs showed an EOP of over ~90%, except for Cas9_ModA, which showed an EOP of ~50%. This difference can be explained by the dependency of the Cas cleavage efficiency on targeted protospacer and was reported to be highly variable within the T4 phage genome for both CRISPR-Cas9 and CRISPR-Cas12 before (Tao, Wu et al. 2017, Liu, Dai et al. 2020). Nevertheless, our results demonstrate a low activity of both systems on T4 phage DNA. To investigate whetherthe presence of NgTET enzyme, which reduces the level of DNA modifications on T4 DNA, would improve Cas cleavage in vivo, the experiment was repeated while infecting E. coli expressing both the CRISPR-Cas system and NgTET simultaneously. The expression of NgTET had a positive effect on all analyzed targets, reducing the efficiency of plating and thereby increasing the Cas cleavage efficiency to ~50-75% depending on the selected spacer. The analogous experiment with inactive mutant NgTET D234A showed similar EOPs to wild-type, confirming that the increased Cas cleavage activity on T4 DNA is linked to altered DNA modification levels connected to NgTET activity. To additionally visualize the effect of NgTET activity on Cas cleavage efficiency in vivo, we characterized the lysis of E. coli by T4 phage and T4 phage progeny from infection of NgTET expressing cells (NgTET T4) (Figure 2A). The lysis was investigated in the presence of the CRISPR-Cas12_Alt system, which exhibits reduced to no activity in vivo during phage infection in the absence of NgTET. For infection with wild-type T4 phage, the presence of an active Cas nuclease does not significantly delay cell lysis during phage infection, which suggests that T4 phage genome hypermodification protects nucleolytic DNA cleavage by Cas12. However, for the infection with NgTET T4 phage (the phage isolated from infection of E. coli overexpressing NgTET), a significant delay in lysis is observed, explained by increased activity of Cas nuclease slowing down the phage propagation. During this delay, the progeny phages restore the wild-type hypermodification pattern as NgTET is not present, resulting in delayed lysis initiation. To verify that the altered lysis behavior is due to NgTET pretreatment of NgTET T4 phages, we performed a lysis assay with E. coli cells expressing NgTET and the same CRISPR-Cas system. Continuous overexpression of the dioxygenase prevented the initiation of lysis for up to 10 hours (Figure 3C).

[0127] Therefore both, EOP and lysis experiments confirm that NgTET-mediated reduction of T4 DNA hypermodifications improves Cas cleavage of T4 DNA / n vivo, which is an initial and one of the crucial steps of CRISPR-Cas-based phage engineering.

[0128] Example 3 - Development of an efficient screening approach

[0129] The overexpression of NgTET in the E. coli mutagenesis strain enhances the crucial step of phage engineering, namely Cas-mediated T4 DNA cleavage. To demonstrate the advantage of this observation on T4 phage engineering efficiency, we followed a previously described CRISPR-Cas- based mutagenesis protocol with modifications to assess the effect of NgTET. We performed mutagenesis of the alt and modA genes in four different settings for each gene: applying the CRISPR- Cas9 or CRISPR-Cas12 system in the presence or absence of NgTET (Figure 3, Table 1). Since the Cas-efficiency was below 100% in all settings (Figure 2B), we subjected the resulting phage population to a counterselection strain overexpressing NgTET and the same CRISPR-Cas system as applied in the previous step. After counterselection, resulting phages were separated by plating with E. coli B strain and subjected to screening.

[0130] In addition to the improvement of mutagenesis efficiency, this work aimed to establish a screening approach capable of detecting mutations of different sizes, particularly SNPs, which are currently limited to detection by direct sequencing. To achieve this, we performed an ONP-based approach where the target region is amplified from the phage with the introduction of the plaque-specific barcodes. This makes it possible to screen for hundreds of phages simultaneously in a high-throughput manner.

[0131] Combining the mutagenesis with ONP sequencing, we found that CRISPR-Cas9- and CRISPR-Cas12- based mutagenesis in the absence of NgTET resulted in 0 positive mutants out of 48 analyzed plaques per CRISPR-Cas system, spacer and targeted gene. However, overexpression of NgTET in the infected E. coli host strain boosted the mutagenesis efficiency and resulted in ~4% positive hits for both targeted genes modA and alt (Table 1). Furthermore, for both cases, only the application of the CRISPR-Cas12 system led to successful mutagenesis.

[0132] In conclusion, this experiment has demonstrated that the coexpression of NgTET dioxygenase in the mutagenesis strain made it possible to generate the T4 point mutants of interest, which were not achievable by mutagenesis in absence of NgTET.

[0133] Table 1 : Summary of NgTET effect on T4 phage genome editing

[0134] Example 4 - TXTL of T4 DNA and NgTET The biosynthesis of T4 phage was conducted in TXTL using 1 nM T4 WT DNA (Figure 4a). Following a 16-hour incubation period, the TXTL reaction resulted in the formation of infectious phages, as verified in the consequent plaque assay (Figure 4b). The number of phages generated per 12 pl TXTL reaction ranged from 100 to 10,000. The TXTL solution exhibited a highly viscous character at a DNA concentration of 1 nM, which indicated a high phage DNA concentration in the reaction. Furthermore, infectious phages were synthesized also using 0.1 nM NgTET-treated T4 DNA.

[0135] In addition to the plaque assay, mass spectrometry-based proteomics analysis was conducted to ascertain the number of T4 phage proteins that could be identified in a TXTL reaction. Of the 273 phage T4 proteins, 181 proteins (66% coverage) were detected in all TXTL reactions, and no T4 proteins were observed in the negative control without DNA. The identified proteins could be assigned to every phase of the infection (early, middle, and late) and included regulatory as well as structural proteins. Thus, both proteomics and plaque assay experiments conducted with TXTL reaction with pure T4 DNA confirmed the biosynthesis of T4 phages in the TXTL reaction.

[0136] Besides synthesizing the T4 phage in the TXTL reaction, we aimed to illustrate the synthesis of NgTET dioxygenase within the same system, suggesting its capability to modulate DNA modifications on phage DNA in TXTL settings. Through LC-MS analysis, we demonstrated the efficient synthesis of NgTET in TXTL, either independently or in conjunction with a Cas nuclease. This result validates the in vitro synthesis of NgTET and its potential to regulate phage DNA modifications within the TXTL reaction.

[0137] Example 5 - Methods

[0138] Table 2: Primers used in this study. Mutation in bold and italic.

[0139] Table 3: Genomic DNA sequence of ARTs, rS1 variants, and ADP-ribose hydrolases. Start codon in italic; thrombin cleavage site in bold; mutations in red and bold; restriction sites underlined.

[0140] Table 4: Strains and plasmids used in this study.

[0141] Cloning of nTET, sgRNAs and sequences for homologous recombination

[0142] The gene encoding for the nTET from Naegleria gruberi was purchased from IDT as gblock and amplified by PCR. Xhol and Ncol restriction sites were introduced during amplification using appropriate primers (Table 1). The resulting PCR product was digested with Xhol and Ncol and introduced into the pET-28a vector (Merck Millipore). The ModA E165A, Alt E577A, NudE L55.56A, and NgTET D243A were generated by site-directed mutagenesis. The insertion of the sgRNA sequences into pCPfl (#122185, Addgene) and DS-SPCas (#48645, Addgene) plasmids was performed via amplification with the primers carrying respective 5’-overhang. All resulting plasmids were sequenced by Sanger sequencing and transformed into E. coli BL21 (DE3). All plasmids and strains generated in this work are listed in Table 3.

[0143] T4 phage propagation

[0144] For T4 phage propagation, E. coli BL21 (DE3) cells were used. The initial culture was set up to ODeoo ~ 0.1 and grown at 37 °C, 160 rpm until ODeoo ~ 0.8 was reached. T4 phage was added to a multiplicity of infection (MOI) of 0.8 and the infection was run for 3 - 4 h at RT, 120 rpm. The lysate was centrifuged at 1 ,200 x g for 5 min and the supernatant was filtered through Steritop filters (pore size 0.22 pm). The concentration of the phages was determined via plaque assay and the phage suspension was stored at

[0145] 4 °C.

[0146] For the propagation of NgTET-treated T4 phages, the infection was performed mostly in the same way. Here, E. coli BL21 (DE3) pET28a_nTET strain was used and the medium was supplied with 50 pM kanamycin. As the culture reached ODeoo ~ 0.4, overexpression of nTET was induced by the addition of 50 pM IPTG. The culture was grown for another 2 h at 37 °C and 160 rpm and infected with T4 phage as described above. To recover NgTET-treated phages, the infection of E. coli BL21 (DE3) was rerun with T4 NgTET phages as described above.

[0147] Plaque assay

[0148] E. coli culture of interest was grown to ODeoo ~ 0.8-1 .0. Next, 300 pl of the culture were infected with 100 pl of T4 WT phage or T4 NgTET phage with either defined or unknown MOI. The bacteria-phage suspension was incubated at 37 °C for 7 min and subsequently transferred to 4 ml of LB-soft-agar (0.75 %), properly mixed, and poured onto an LB-agar plate (1.5 % LB-agar). If needed, agar was supplied with an antibiotic. The plates were incubated at 37 °C o / n and validated on the following day.

[0149] Phage DNA isolation

[0150] 0-45% sucrose gradient was generated in TM buffer (50 mM Tris-HCI, 10 mM MgCL, pH 7.5). 500 pl of the phage solution (PFU / ml > 1010) were carefully loaded on top of the gradient. The gradient was centrifugated at 70,000 x g, 20 min, 4 °C, and the phage band was removed a blunt cannula from the gradient and transferred into a new ultracentrifugation tube. 30 ml of ice-cold TM buffer were added and the phages were pelleted at 100,000 x g for 1 h at 4 °C. The supernatant was discarded and the pellet was resuspended in 500 pl TM buffer and incubated at 4 °C overnight. Afterward, 20 U DNase I (ThermoFisher Scientific, MA, USA) and 2 pl RNase A / T1 Mix (4 pg RNase A, 10 U RNase T1 , ThermoFisher Scientific, MA, USA) were added and suspension incubated at 37 °C for 30 min. 1 pg of Proteinase K (Carl Roth, Karlsruhe, Germany) was added and the samples were incubated for another 30 minutes at 37 °C. For DNA isolation, a phenol / chloroform / isoamyl alcohol (P / C / l) (Carl Roth, Karlsruhe, Germany) extraction was performed three times. The remaining phenol was removed by chloroform back-extraction (3x). The DNA was precipitated with 0.1 volume of 3M NaOAc (pH 5.5) and 2.5 volumes of absolute ethanol at - 20 °C for overnight. The DNA was pelleted at 15,000 x g at 4 °C for 1 h and the pellet was washed twice with 70% ethanol. The purified DNA was resuspended in Millipore water and stored at -20 °C until further use.

[0151] NgTET and NgTET D243A overexpression and purification

[0152] E. coli BL21 (DE3) containing the respective plasmid (Supplementary Table 3) were cultured in LB medium at 37 °C until ODeoo = 0.5. Afterward, the temperature was shifted to 16°C, and expression induced by the addition of isopropyl p-D-1 -thiogalactopyranoside (IPTG) was to 0.4 mM. Cells were harvested by centrifugation after 12 hours at 16°C and lysed by sonication (30 s, 50 % power, three times) in HisTrap buffer A (50 mM Tris-HCI pH 7.8, 1 M NaCI, 1 M Urea, 5 mM MgSO4, 5 mM p- mercaptoethanol, 5 % glycerol, 5 mM imidazole, 1 tablet per 500 ml complete EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland)). The lysate was clarified by centrifugation (37,500 g, 30 min, 4 °C). The supernatant was applied to a 1 ml Ni-NTA HisTrap column (GE Healthcare, IL, USA). The protein was eluted with an imidazole gradient using an analogous gradient of HisTrap buffer B (HisTrap buffer A with 500 mM imidazole). Purification was analyzed by 12% SDS-PAGE.

[0153] The fractions containing target protein were used for size exclusion chromatography (SEC) through a Superdex™ 200 10 / 300 GL column (GE Healthcare, IL, USA) using an SEC buffer containing 0.5 M NaCI and 25 mM Tris-HCI, pH 8. The purification was analyzed via SDS-PAGE. Fractions containing target protein were pooled and concentrated in Amicon Ultra-4 centrifugal filters (MWCO 10 kDa, centrifugation at 2,000 rpm., 4 °C). Protein concentration was measured with the NanoDrop ND-1000 Spectrophotometer. Proteins were stored in SEC buffer supplemented with 50 % glycerol at -20 °C.

[0154] T4 phage mutagenesis

[0155] E. coli pET-28a_nTET_x + pCpf1_x (x: donor DNA and respective sgRNA) strains were used for mutagenesis. The cells were cultivated at 37 °C and 160 rpm until GD600 ~0.4, after which induction with 50 pM IPTG was performed. The cultivation was proceeded until GD600 of 0.8. At this point, the cultures were adjusted to room temperature and 120 rpm. The cells were infected with T4 NgTET phage to MOI of 0.5. The infection was performed for 3 h, after which the cells were pelleted and supernatant filtered through Steritop filters (pore size 0.22 pm). The titer of the newly generated phages was determined via plaque assay and the phages were used for the counterselection via infection of E. coli pET-28a_NgTET + pCpf1_x strain. The counterselected phages were filtered and used for a plaque assay with E. coli B strain. The single plaques were picked and transferred to 100 pl Pi-Mg buffer (26 mM Na2HPO4, 68 mM NaCI, 22 mM KH2PO4, 1 mM MgSO4, pH 7.5) supplemented with 2% chloroform. The suspension was incubated for 1 h at room temperature and was further used for mutagenesis analysis via screening, infection of E. coli, or stored at 4 °C.

[0156] LC-MS

[0157] For LC-MS / MS analysis, the phage DNA was isolated as described in section 2.2.2. Subsequently, 250 ng of phage DNA were digested with the Nucleoside digestion Mix (NEB) for 1 h at 37 °C (final nucleoside concentration 10 pM). Liquid chromatography (2 pl injection volume) was carried out on an Agilent Infinity II 1290 HPLC System, equipped with a UV detector and a Waters Atlantis T3 column 3 pm (2.1 x 150 mm) at 40 °C with a gradient flow (0.2 ml / min) from 75% water and 25% methanol to 25% water and 75% methanol, each supplemented with 10 mM aqueous ammonium acetate (pH 4.5). The nucleosides were analyzed by an Agilent 6470B Triple Quadrupole Mass Detector operating in positive (+ESI) or negative (-ESI) electrospray ionization modes, respectively, coupled with collision-induced dissociation (CID) and multiple reaction monitoring (MRM). MS data acquisition was recorded in total ion chromatogram (TIC) mode. Each nucleoside was identified as follows: dA [M - H]- 250.1 (—>134.1); dC [M - Hj- 226.2 (->135.0, 93.0); dG [M - Hj- 266.1 (- 150.1 ); dT [M - Hj- 241 .1 (^151 .1 , 42.1); 5hmdC [M - H] - 257.0 (- 116.9, 92.9); 5ghmdC [M + H]+ 420.0 (->304.1 , 141 .7). LC-MS data were analyzed using MassHunter Qualitative Analysis software and the relative abundance of the deoxynucleotides was quantified by peak area integration.

[0158] In vitro NgTET activity assay

[0159] The activities of NgTET and its NgTET D243A mutant were analyzed on CpG Methylated Human Genomic DNA (ThermoFisher). The reaction was performed in a 20 pl scale containing 50 mM MOPS, pH 6.75, 50 mM NaCI, 1 mM DTT, 2 mM ascorbic acid, 1 mM aKG, and 100 pM FeSO4, 8 pM NgTetl and 50 pM of the methylated DNA. All reactions were incubated at 34°C for 1 h. Reactions were quenched by heating at 95°C for 3 min and cooled down on the ice. The proteins were digested with 0.5 U of proteinase K (NEB) for 1 h at 37°C, and the DNA was purified via precipitation with isopropanol and 3 M NaOAc. The purified DNA was resolved in Millipore water and digested to nucleoside level as described previously. The nucleoside composition of the NgTET-treated DNA was analyzed on LC-MS.

[0160] T4 phage sequencing

[0161] 1 pl of isolated T4 Phage in Pi-Mg buffer was used. PCR was performed using 0.125 pM forward and reverse barcoding primers in 1x High Fidelity Master Mix (NEB). The amplified sequences were submitted to RG Schindler for further processing.

[0162] Analysis of Oxford NanoPore sequencing data

[0163] NanoPore reads were basecalled using guppy (version info by D. Schindler). In a miniconda environment, reads were demultiplexed using minibar (https: / / github.com / calacademy- research / minibar) and mapped to the T4 phage reference genome (NC_000866.4) using minimap2 (version 2.24)(Li 2018) adjusted to Oxford Nanopore read mapping. The resulting SAM files were converted to BAM files, sorted, and indexed with samtools (version 1.4.1). Variant calling in the target region for mutagenesis was subsequently performed using longshot (version 0.4.1) (Edge and Bansal 2019) and resulting VCF files were inspected for desired point mutants with Integrative Genomics Viewer (IGV 2.16.0). Further, read counts per sample and target region were obtained from sorted BAM files using featurecounts (subread, version 2.0.1)(Liao, Smyth et al. 2014) and a custom R script. Detailed code and an easy command line application for these data analysis steps are provided to the community with CRISPRT4 (https: / / gitlab.eom / MaikTungsten / crisprt4 / - / tree / m Analysis of Nanopore sequencing data).

[0164] In vitro transcription-translation (TXTL)

[0165] The T7 expression kit for linear DNA (myTXTL, Arbor Biosciences) was used to perform TXTL reactions in a 12 pl scale, following the instructions provided in the kit manual. Phage or plasmid DNA was subsequently added to the reaction mixture to achieve a final concentration of 0.1 nM-1 nM. Subsequently, the reactions were incubated at 30°C for 16 hours for T4 phage expression and 4 hours for expression from a plasmid.

[0166] To confirm the production of phages in the TXTL reaction, 20 units of DNase I were added, and the mixture was incubated at 37°C for 20 minutes to reduce viscosity. The assembly of infectious phages was then validated via a plaque assay. Furthermore, the production of overexpressed proteins from plasmids in the TXTL system was confirmed by LC-MS analysis.

[0167] TXTL Proteomics

[0168] To 10 pl of the TXTL solution, 200 pl lysis buffer (50 mM Tris-HCI, pH 7.5, 1 % SLS, 2 mM TCEP) was added and heated to 95°C, 10 min. A sonication step (10 sec, 20% amplitude, 0.5 pulse) was performed to degrade nucleic acids in the samples. Following this, iodoacetamide was added to the final concentration of 4 mM, and the samples were incubated for 30 minutes under light protection. The proteins were precipitated using acetone. The resulting pellets were washed with 500 pL of methanol (- 80 °C), air-dried, and resuspended in 50 pL of resuspension buffer (50 mM Tris-HCI, pH 7.5, 0.5% SLS). The protein concentration was determined using the BCA assay (Pierce TM, BCA protein assay kit, ThermoFisher Scientific, Waltham, MA, USA). To 10 pg of isolated proteins, 0.5 pg of sequencing-grade trypsin (Promega) was added. Digestion was carried out overnight at 30 °C. The remaining SLS was precipitated by adding 1.5% TFA (v / v) and subsequent centrifugation at 4°C, 17,000 x g, 10 min. The resulting supernatant was desalted for mass spectrometric analysis using C18 solid-phase columns (Chromabond C18 spin columns, Macherey Nagel, Duren, Germany). After desalting, the solvent was removed by evaporation and dried peptides were stored at -20 °C until further use.

[0169] Peptide analysis using liquid chromatography and mass spectrometry

[0170] Dried peptides were reconstituted in 0.1 % trifluoroacetic acid and then analyzed using liquid- chromatography-mass spectrometry carried out on a Exploris 480 instrument connected to an Ultimate 3000 RSLC nano and a nanospray flex ion source (all Thermo Scientific). Peptide separation was performed on a reverse phase HPLC column (75 pm x 42 cm) packed in-house with C18 resin (2.4 pm; Dr. Maisch). The following separating gradient was used: 98% solvent A (0.15% formic acid) and 5% solvent B (99.85% acetonitrile, 0.15% formic acid) to 30% solvent B over 45 minutes at a flow rate of 300 nl / min.

[0171] The data acquisition mode was set to obtain one high-resolution MS scan at a resolution of 60,000 full width at half maximum (at m / z 200) followed by MS / MS scans of the most intense ions within 1 s (cycle 1s). To increase the efficiency of MS / MS attempts, the charged state screening modus was enabled to exclude unassigned and singly charged ions. The dynamic exclusion duration was set to 14 sec. The ion accumulation time was set to 50 ms (MS) and 50 ms at 17,500 resolution (MS / MS). The automatic gain control (AGC) was set to 3x106 for MS survey scan and 2x105 for MS / MS scans.

[0172] For spectral-based assessment, MS raw files searches were carried out using MSFragger embedded within Scaffold 4 (Proteome Software) with 20 ppm peptide and fragment tolerance with Carbamidomethylation (C) as fixed, and oxidation (M) as variable modification using a uniprot protein database.

[0173] Example 6 - Conclusion and discussion In this study, we have presented an innovative approach to improve the efficiency of CRISPR-Cas- mediated phage engineering. This is based on the reduction of the abundant and sterically demanding 5ghmdC modifications. The key in our presented procedure is NgTET-mediated oxidation of 5hmdC during T4 phage infection of E. coli. This method significantly enhances the cleavage of T4 DNA via Cas12 and Cas9 nucleases in vivo. The striking advantage of the approach is that it alters cytosine modification levels for only one generation of the phage, whereupon the recovery of modification level is easily achieved via infection by NgTET T4 phage of E. coli, which does not overexpress NgTET. This ensures that there is no long-term impact on phage fitness, which is a critical consideration for any phage engineering application and analysis of the impact of introduced mutations. We believe that NgTET-mediated reduction of modification levels within T4 phage DNA represents a promising approach for enhancing CRISPR-Cas-mediated phage engineering efficiency not only for T4 phage but also for other phages that carry similar cytosine modifications.

[0174] Furthermore, here we describe an application of ONP-sequencing for high-throughput screening of phage mutants. Its biggest benefit is the non-invasive nature of this method, allowing nucleic acid editing without requiring any additional manipulation of the viral genome, such as the introduction of reporter genes. One of the further benefits of here described screening approach toward other powerful counterselection strategies allowing for the identification of mutants by reduction of the total viral population, is the possibility to detect minimal changes in the genome. For instance, applying a powerful Cas13-based counterselection approach becomes challenging for the identification of 1-3 nucleotides mutations (Adler, Hessler et al. 2022). Therefore, the possibility to detect SNPs with ONP-sequencing opens up new avenues for research in minimal genome editing and elucidation of the function of the genes and proteins.

[0175] While our study demonstrates increased cleavage efficiency of phage DNA in vivo by both Cas9 and Cas12 systems, we observed that only the application of the CRISPR-Cas12 system in presence of NgTET led successfully to the generation of the modA and alt phage mutants. This can be connected to better acceptance by Cas12 of modified DNA as a substrate compared to Cas9 observed in previous studies (Vlot, Houkes et al. 2018).

[0176] For CRISPR-Cas12 mediated mutagenesis we observed the mutagenesis rate of ~4% for modA and ~4% for alt (Table 1), whereupon the cleavage efficiency on T4 DNA in vivo in presence of NgTET was ~50% and ~75% for both genes respectively (Figure 2 B). The discrepancy in both observations can be explained by the fact that while Cas cleavage of T4 DNA is an essential step that allows for mutagenesis initiation, the recombination efficiency is another key step required for efficient completion of mutagenesis. Our system relies only on the native E. coli and T4 phage recombination apparatus. Therefore, while this approach already enables the generation of the point mutants of T4 phage that were not achievable with previously described CRISPR / Cas-based approaches, the expression of the additional proteins that might facilitate the recombination step might could boost the mutation rate in the future. Overall, the demonstrated possibility to introduce SNPs to the T4 phage genome and efficiently screen for them is highly significant for shifting the focus from studying gene function through deletion towards inactivating the catalytic activity of a viral enzyme by point mutations. This shift is crucial because the genetics of the phages are highly complex and deletion of a complete gene might strongly affect the expression of other genes. On the other hand, proteins may have biocatalytic relevance, but at the same time be important interaction partners. Therefore, the traditional approach of studying gene function through deletion may not always capture the role of certain proteins in fully complex host-pathogen interactions. Thus, by targeting the catalytic activity of specific proteins, exemplified in this study on Alt and ModA, and understanding their impact on phage infection, we can gain a more comprehensive understanding of phage biology and improve our ability to engineer phages for various applications.

[0177] References

[0178] Adler, B. A., T. Hessler, B. F. Cress, A. Lahiri, V. K. Mutalik, R. Barrangou, J. Banfield and J. A. Doudna (2022). "Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing." Nat Microbiol 7(12): 1967-1979.

[0179] Box, A. M., M. J. McGuffie, B. J. O'Hara and K. D. Seed (2016). "Functional Analysis of Bacteriophage Immunity through a Type l-E CRISPR-Cas System in Vibrio cholerae and Its Application in Bacteriophage Genome Engineering." J Bacteriol 198(3): 578-590.

[0180] Bryson, A. L., Y. Hwang, S. Sherrill-Mix, G. D. Wu, J. D. Lewis, L. Black, T. A. Clark and F. D. Bushman (2015). "Covalent Modification of Bacteriophage T4 DNA Inhibits CRISPR-Cas9." mBio 6(3): e00648.

[0181] Chen, Y. B., H. Batra, J. H. Dong, C. Chen, V. B. Rao and P. Tao (2019). "Genetic Engineering of Bacteriophages Against Infectious Diseases." Frontiers in Microbiology 10.

[0182] Dong, J., C. Chen, Y. Liu, J. Zhu, M. Li, V. B. Rao and P. Tao (2021). "Engineering T4 Bacteriophage for In Vivo Display by Type V CRISPR-Cas Genome Editing." ACS Synth Biol 10(10): 2639-2648.

[0183] Drake, J. W. (1966). "Ultraviolet mutagenesis in bacteriophage T-4. I. Irradiation of extracellular phage particles." J Bacteriol 91 (5): 1775-1780.

[0184] Duong, M. M., C. M. Carmody, Q. Ma, J. E. Peters and S. R. Nugen (2020). "Optimization of T4 phage engineering via CRISPR / Cas9." Sci Rep 10(1): 18229.

[0185] Edge, P. and V. Bansal (2019). "Longshot enables accurate variant calling in diploid genomes from single-molecule long read sequencing." Nat Commun 10(1): 4660.

[0186] Endersen, L., J. O'Mahony, C. Hill, R. P. Ross, O. McAuliffe and A. Coffey (2014). "Phage Therapy in the Food Industry." Annual Review of Food Science and Technology, Vol 5 5: 327-349.

[0187] Flodman, K., I. R. Correa, Jr., N. Dai, P. Weigele and S. Y. Xu (2020). "In vitro Type II Restriction of Bacteriophage DNA With Modified Pyrimidines." Front Microbiol 11 : 604618.

[0188] Gordillo Altamirano, F. L. and J. J. Barr (2019). "Phage Therapy in the Postantibiotic Era." Clin Microbiol Rev 32(2).

[0189] Hashimoto, H., J. E. Pais, N. Dai, I. R. Correa, X. Zhang, Y. Zheng and X. D. Cheng (2015). "Structure of Naegleria Tet-like dioxygenase (NgTetl) in complexes with a reaction intermediate 5- hydroxymethylcytosine DNA." Nucleic Acids Research 43(22). Hashimoto, H., J. E. Pais, X. Zhang, L. Saleh, Z. Q. Fu, N. Dai, I. R. Correa, Y. Zheng and X. D. Cheng (2014). "Structure of a Naegleria Tet-like dioxygenase in complex with 5-methylcytosine DNA." Nature 506(7488): 391 -+.

[0190] Hatoum-Aslan, A. (2018). "Phage Genetic Engineering Using CRISPR-Cas Systems." Viruses-Basel 10(6).

[0191] Hutinet, G., Y. J. Lee, V. de Crecy-Lagard and P. R. Weigele (2021). "Hypermodified DNA in Viruses of E. coli and Salmonella." EcoSal Plus 9(2): eESP00282019.

[0192] Ito, S., A. C. D'Alessio, O. V. Taranova, K. Hong, L. C. Sowers and Y. Zhang (2010). "Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification." Nature 466(7310): 1129-1133.

[0193] Kiro, R., D. Shitrit and U. Qimron (2014). "Efficient engineering of a bacteriophage genome using the type l-E CRISPR-Cas system." RNA Biol 11 (1): 42-44.

[0194] Kornberg, S. R., S. B. Zimmerman and A. Kornberg (1961). "Glucosylation of deoxyribonucleic acid by enzymes from bacteriophage-infected Escherichia coli." J Biol Chem 236: 1487-1493.

[0195] Lemay, M. L., D. M. Tremblay and S. Moineau (2017). "Genome Engineering of Virulent Lactococcal Phages Using CRISPR-Cas9." ACS Synth Biol 6(7): 1351-1358.

[0196] Li, H. (2018). "Minimap2: pairwise alignment for nucleotide sequences." Bioinformatics 34(18): 3094- 3100.

[0197] Liao, Y., G. K. Smyth and W. Shi (2014). "featurecounts: an efficient general purpose program for assigning sequence reads to genomic features." Bioinformatics 30(7): 923-930.

[0198] Liu, Y., L. Dai, J. Dong, C. Chen, J. Zhu, V. B. Rao and P. Tao (2020). "Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems." J Virol 94(23). Mahler, M., A. R. Costa, S. P. B. van Beljouw, P. C. Fineran and S. J. J. Brouns (2022). "Approaches for bacteriophage genome engineering." Trends Biotechnol.

[0199] Mahony, J., E. Casey and D. van Sinderen (2020). "The Impact and Applications of Phages in the Food Industry and Agriculture." Viruses 12(2).

[0200] Martel, B. and S. Moineau (2014). "CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages." Nucleic Acids Res 42(14): 9504-9513.

[0201] Miller, E. S., E. Kutter, G. Mosig, F. Arisaka, T. Kunisawa and W. Ruger (2003). "Bacteriophage T4 genome." Microbiol Mol Biol Rev 67(1): 86-156, table of contents.

[0202] Miller, E. S., E. Kutter, G. Mosig, F. Arisaka, T. Kunisawa and W. Riiger (2003). "Bacteriophage T4 Genome." Microbiology and Molecular Biology Reviews 67(1): 86-156.

[0203] Pires, D. P., S. Cleto, S. Sillankorva, J. Azeredo and T. K. Lu (2016). "Genetically Engineered Phages: a Review of Advances over the Last Decade." Microbiology and Molecular Biology Reviews 80(3): 523- 543.

[0204] Tahiliani, M., K. P. Koh, Y. Shen, W. A. Pastor, H. Bandukwala, Y. Brudno, S. Agarwal, L. M. Iyer, D. R. Liu, L. Aravind and A. Rao (2009). "Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 ." Science 324(5929): 930-935.

[0205] Tao, P., X. Wu, W. C. Tang, J. Zhu and V. Rao (2017). "Engineering of Bacteriophage T4 Genome Using CRISPR-Cas9." ACS Synth Biol 6(10): 1952-1961. Tiemann, B., R. Depping, E. Gineikiene, L. Kaliniene, R. Nivinskas and W. Ruger (2004). "ModA and ModB, two ADP-ribosyltransferases encoded by bacteriophage T4: catalytic properties and mutation analysis." J Bacteriol 186(21): 7262-7272.

[0206] Vlot, M., J. Houkes, S. J. A. Lochs, D. C. Swarts, P. Zheng, T. Kunne, P. Mohanraju, C. Anders, M. Jinek, J. van der Oost, M. J. Dickman and S. J. J. Brouns (2018). "Bacteriophage DNA glucosylation impairs target DNA binding by type I and II but not by type V CRISPR-Cas effector complexes." Nucleic Acids Res 46(2): 873-885.

[0207] Wolfram-Schauerte, M., N. Pozhydaieva, M. Viering, T. Glatter and K. Hofer (2022). "Integrated Omics Reveal Time-Resolved Insights into T4 Phage Infection of E. coli on Proteome and Transcriptome Levels." Viruses 14(11).

[0208] Yu, M., G. C. Hon, K. E. Szulwach, C. X. Song, P. Jin, B. Ren and C. He (2012). "Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine." Nat Protoc 7(12): 2159-2170.

[0209] Zemach, A., I. E. McDaniel, P. Silva and D. Zilberman (2010). "Genome-wide evolutionary analysis of eukaryotic DNA methylation." Science 328(5980): 916-919.

Claims

CLAIMS1 . A method for genetically engineering the genome of phages at a target locus by CRISPR-Cas comprising(a) introducing into a bacterial cell, a L-form bacterium, a cell-free transcription-translation system (TXTL) system or a bacterial cell lysate expressing or comprising a Tet-like protein and comprising the phages the genome of which is to be genetically engineered(I) one or more nucleic acid molecules, said one or more nucleic acid molecules encoding in expressible form(i) a CRISPR-Cas nuclease, and(ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and(iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus;(II)(i) a CRISPR-Cas nuclease,(ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and(iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus,(HI)(i) a CRISPR-Cas nuclease, and(ii) a nucleic acid molecule encoding in expressible form a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and(iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus;(IV)(i) a nucleic acid molecule encoding in expressible form a CRISPR-Cas nuclease, and(ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and(iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; or(V)(i) a ribonucleoprotein complex (RNP) comprising or consisting of a CRISPR-Cas nucleasein complex with a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease, and(ii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus; and(b) maintaining the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate under conditions wherein the genome of the phages becomes genetically engineered by the CRISPR-Cas nuclease, optionally by homology directed repair (HDR) in the case the donor template is present.

2. The method of claim 1 , further comprising prior to step (a)(a-a) introducing into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate a nucleic acid molecule encoding in expressible form a Tet-like protein, and / or(a-b) introducing into the bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate the phages the genome of which is to be genetically engineered.

3. The method of claim 2, wherein comprising prior to step (a-b)(a-c) propagating the phages the genome of which is to be genetically engineered in a bacterial cell, a L-form bacterium, TXTL system or a bacterial cell lysate expressing a Tet-like protein, and (a-d) isolating the propagated phages and employing the propagated phages in step (a-b).

4. The method of any one of claims 1 to 3, wherein a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus is used and wherein the method further comprises(c) isolating the phages after step (b), and(d) introducing into the bacterial cell, the L-form bacterium, the TXTL system or the bacterial cell lysate expressing a Tet-like protein, a CRISPR-Cas nuclease, and a guide RNA comprising (i) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (ii) a second segment that interacts with the CRISPR-Cas nuclease of (i), thereby enriching the phages that have been genetically engineered by homology directed repair (HDR).

5. The method of any one of claims 1 to 4, wherein the method further comprises(e) isolating the phages after step (b) or (d), and(f) separating the phages from each other in order to obtain separated phages, preferably by introducing them into bacterial cells, the L-form bacterium, TXTL systems or bacterial cell lysates and plating them out, by fluorescent activated cell sorting, microfluidics or by a dilution series.

6. The method of claim 5, wherein a nucleic acid molecule comprising, consisting of, or encoding adonor template with homology to the target locus is used wherein the method further comprises(g) amplifying the target locus of the separated phages by primers pairs being labeled with primer pair-specific barcodes, and(h) sequencing the amplification product of (g) thereby identifying the phages wherein the target locus has been genetically engineered by the donor template.

7. The method of any one of claims 1 to 6, wherein the method further comprises(k) propagating the phages the genome of which has been genetically engineered in a bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate that does not express a Tet-like protein, thereby restoring 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC) in the genomic DNA.

8. A bacterial cell, L-form bacterium, TXTL system or bacterial cell lysate expressing a Tet-like protein and comprising a phage.

9. The cell, L-form bacterium, TXTL system or bacterial cell lysate of claim 8 further comprising(i) a CRISPR-Cas nuclease, and(ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i), and(iii) optionally a nucleic acid molecule comprising, consisting of, or encoding a donor template with homology to the target locus.

10. A kit for genetically engineering the genome of phages at a target locus comprising(A) one or more nucleic acid molecules, said one or more nucleic acid molecules encoding in expressible form(i) a CRISPR-Cas nuclease,(ii) optionally a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR-Cas nuclease of (i) or a cloning site for the addition of said guide RNA into the one or more nucleic acid molecules, and(iii) optionally a donor template with homology to the target locus or a cloning site for the addition of said donor template into the one or more nucleic acid molecules, and(B) a nucleic acid molecule encoding in expressible form a Tet-like protein.11 . The method, cell, L-form bacterium, TXTL system or bacterial cell lysate, or kit of any one of the preceding claims, wherein the Tet-like protein comprises of consists(a) the amino caid sequence of SEQ ID NO: 1 ,(b) the amino caid sequence being encoded by SEQ ID NO: 2, or(c) an amino caid sequence being at least 80%, preferably at least 90% and most preferably at least 95% identical to the amino acid sequence of (a) or (b).

12. The method, cell, L-form bacterium, TXTL system or bacterial cell lysate, or kit of any one of the preceding claims, wherein the phages prior to the contact with a Tet-like protein are characterized by genomic DNA with 5-methyl deoxycytosine (5mdC), 5-hydroxymethyl-2’-deoxycytosine (5hmdC), and / or 5-a- / p-glycosyl hydroxymethyl-2’-deoxycytosine (5ghmdC).

13. The method, cell, L-form bacterium, TXTL system or bacterial cell lysate, or kit of any one of the preceding claims, wherein the phages are members of the family of Myoviridae, preferably members of the subfamily Tevenvirinae, are most preferably Tequatroviruses, and most preferably T4 phages.

14. The method, cell, L-form bacterium, TXTL system or bacterial cell lysate, or kit of any one of the preceding claims, wherein the bacterial cell, TXTL system or bacterial cell lysate is or is derived from a Gram-negative cell, preferably from the order Enterobacterales, more preferably from the family of Enterobacteriaceae and is most preferably an E. coli cell or derived therefrom.

15. The method, cell, L-form bacterium, TXTL system or bacterial cell lysate or kit of any one of the preceding claims, wherein the CRISPR-Cas nuclease is a Class 2, Type II or a Class 2, Type V CRISPR / Cas nuclease, is preferably Cas9 or Cas12 and is most preferably Cas12.